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ABSTRACT 
The purpose of this study was to examine the relationship between adherence and 
traumatic stress, depression, and symptom distress. The study also sought to determine 
whether or not non adherence was intentional or unintentional. A non-experimental 
correlational regression design was used to design and conduct the study. Prior research 
(Armaiz-Pena, Lutgendorf, Cole, Sood, 2009; McGregor & Antoni, 2009; Miller, Ancoli-
Israel, Bower, Capuron, Irwin, 2007), indicated behavioral outcomes are related to 
psychological stress, behavioral response, and the bi-directional biological influences 
affecting neurocognitive functioning. There is currently little knowledge about predictors 
of adherence and intentionality to adjuvant hormonal therapy. A biobehavioral theoretical 
model was used to provide the foundation for the study on adherence and intentionality to 
adjuvant hormonal therapy in breast cancer treatment. The term intentionality was used to 
describe the participants’ desire to maintain adherence to adjuvant hormonal therapy 
during the study.  
Participants were recruited from five outpatient breast cancer treatment settings, 
healthcare organizations, or programs providing treatment or support services for breast 
cancer survivors. Inclusion criteria for this study include: (a) female 20–70 years  
(b) breast cancer diagnosis (c) completion of all single or multimodal adjuvant or neo-
adjuvant treatment plans (d) English speaking and writing, and (e) first diagnosis of 
cancer. Stepwise multiple regression tests were used to analyze the data collected for the 
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study and is appropriate for the variables and purpose to be used in the study. The study 
used traumatic stress, depression and symptom distress as predictor variables and 
adherence and intentionality as the dependent variables. This study will contribute to the 
knowledge of adherence and intentionality to adjuvant hormonal therapy in breast cancer 
treatment, and improve clinical outcomes.  
 
The form and content of this abstract are approved. I recommend its publication. 




First, I want to express my deepest gratitude to the women that participated in this 
study, without them this research would not have happened. Trusting me and sharing 
their stories inspired me to continue this work. I want to thank my advisors for their time 
and effort in guiding me to contribute new ideas to nursing science. Their expectations of 
me helped me to realize the journey is not merely about the destination, it’s about what 
we learn throughout the journey. My sincere appreciation goes out Rocky Mountain 
Cancer Centers staff for their support of this project. I want to extend my sincere 
gratitude to Dr. Scott Sedlacek for his support, inspiration and trust while working with 
his patients. I want to express sincere gratitude to the late Dr. Betsy Pearman for her 
support and advice with this process. Thank you to Margaret Pevec for her assistance, 
patience and support. Appreciation to Russell Strickland for his problem solving, 
knowledge and great teaching ability. Enormous gratitude to my amazing trio that 
provided endless support, Patricia Gassaway, Jennifer Schofield and Lynn Bentley. 
Appreciation to my late Aunt, Euncie Tilston for the support of education in my life. 
Many thanks to. other family and friends that provided support over the years during this 
process.  
Sincere gratitude to my parents for their support love and teachings of compassion 
and perseverance. Most of all to my three children Rachel, Sophia and Justin for their 
inspiration to set an example for success, you are my greatest treasures. Finally, I want to 
express great appreciation for all the nurse scientists and nurse theorists over the years at 
the University of Colorado Anschutz Medical Campus College of Nursing for their 
knowledge of caring science. I express immense gratitude for the knowledge of nursing 
 
 vi 
theory that was passed on to me; this knowledge has sustained me and been my compass 
as a nurse and healer throughout the years. This ingredient made all the difference in the 
world to effectively navigate the process of assisting others to heal. 
 
 vii 
TABLE OF CONTENTS 
CHAPTER 




Specific Aims................................................................................................................ 4	  
Adherence Research Barriers........................................................................................ 7	  
Breast Cancer Diagnosis and Treatment....................................................................... 9	  
Significance of the Problem........................................................................................ 10	  
Cancer and Stress........................................................................................................ 11	  
Research Contribution ................................................................................................ 16	  
II.  LITERATURE REVIEW............................................................................................ 17	  
Adherence Factors ...................................................................................................... 19	  
Emotional Factors ....................................................................................................... 21	  
Conceptual Analysis of Adherence............................................................................. 21	  
Adherence Definition Summary ................................................................................. 24	  
Conceptual Theoretical Framework............................................................................ 24	  
Proposed Theoretical Framework............................................................................... 27	  
Implications for Nursing............................................................................................. 35	  
Metaparadigm Assumptions ................................................................................. 38	  
Knowledge Gap .................................................................................................... 41	  
Definitions .................................................................................................................. 42	  
 
 viii 
III.  METHODOLOGY .................................................................................................... 45	  
Introduction................................................................................................................. 45	  
Research Method ........................................................................................................ 47	  
Research Design ......................................................................................................... 48	  
Study Participants ................................................................................................. 49	  
Informed Consent ................................................................................................. 50	  
Confidentiality ...................................................................................................... 51	  
Data Collection ........................................................................................................... 52	  
Advertisement and Recruiting .............................................................................. 52	  
Measures ............................................................................................................... 53	  
Adherence Data..................................................................................................... 54	  
Descriptive Variables............................................................................................ 55	  
Instruments.................................................................................................................. 55 
Center for Disease for Epidemiological Studies– 
Depression Scale (CES-D).................................................................................... 56	  
Impact of Events Scale ......................................................................................... 57	  
Psychological Symptom Distress Scale (PDS)..................................................... 59	  
Medication Event Monitoring System.................................................................. 61	  
Pill Count Form .................................................................................................... 61	  
Medication Possession Ratio ................................................................................ 61	  
Intentionality ............................................................................................................... 62	  
Validity and Reliability............................................................................................... 63	  




IV. RESULTS................................................................................................................... 72 
      Sample Characteristics................................................................................................ 72	  
Data Collection and Response Rate............................................................................ 74	  
Descriptives .......................................................................................................... 75	  
Reliability ............................................................................................................. 85	  
Hypothesis Testing ............................................................................................... 85	  





V. DISCUSSION .............................................................................................................. 92	  
Major Findings............................................................................................................ 92	  
What is Known About Adherence .............................................................................. 94	  
Biobehavioral Mechanisms of Adherence............................................................ 95	  
Methods of Measurement ........................................................................................... 96	  
Findings ...................................................................................................................... 98 
Impact of Traumatic Stress, Depression and  
Symptom Distress on Adherence.......................................................................... 98 
Impact of Traumatic Stress, Depression  
and Symptom Distress on Intentional/Unintentional Adherence ....................... 100	  
Sample Characteristics........................................................................................ 101	  
Limitations ................................................................................................................ 101	  




REFERENCES ............................................................................................................... 106	  
APPENDIX 
A.    Advertisement Flyer ........................................................................................ 122	  
B.    Inclusion Criteria And Obtaining Informed Consent ...................................... 123	  
C.    Informed Consent ............................................................................................ 124	  
D.    HIPAA Authorization To Release Health Information Form ......................... 131	  
E.    Breast Cancer Survey (MS Word Version For Clarity)................................... 132	  
F.    Breast Cancer Survey (PDF Version) .............................................................. 135	  
G.    CES-D.............................................................................................................. 138	  
H.    Impact Of Event Scale..................................................................................... 139	  




LIST OF TABLES 
TABLE 
1.  Demographic/Descriptive Frequencies ............................................................73 
2. Descriptive Statistics for Study Variables .......................................................76 
3. Reliability Measures ........................................................................................85 
4. Correlation Matrix: CES, IES, and NAR.........................................................87 
5. Correlations: PDS and NAR ............................................................................87 
6. Multiple Regression Model: CES and IES as Predictors  
 of MEMS Non-adherence Ratio ......................................................................88 
 
7. Multiple Regression Model: CES, Avoidance, and Intrusive as Predictors  
 of MEMS Non-adherence Ratio ......................................................................88 
 
8. Multiple Regression Model: CES and IES as Predictors 
 of Intentional, Unintentional, and Total Non-adherence Ratios ......................89 
 
9. Multiple Regression Model: CES, Avoidance, and Intrusive as Predictors  





LIST OF FIGURES 
FIGURE 
1.  Biobehavioral Model of Cancer Stress ............................................................28 
2.  Adapted Biobehavioral Model of Cancer Stress..............................................32 
3.  Age Distribution of Participants ......................................................................78 
4. CES-D Distribution of Participants .................................................................79 
5. IES Distribution of Participants .......................................................................80 
6. MEMS Non-adherence Ratio...........................................................................81 
7. Unintentional Non-adherence Ratio ................................................................82 
8. Intentional Non-adherence Ratio .....................................................................83 







Breast cancer is the second leading cause of death for women and has the highest 
incidence rate of any cancer experienced by women (NCI, 2009). This disease accounts 
for 28% of all newly diagnosed cancers and is a serious health concern for women of 
all ages (Siegel, Naishadham, Jemal, 2012). In 2015, it is estimated that 231,840 women 
will be diagnosed with invasive breast cancer, additionally 60,290 women will be 
diagnosed with in situ breast cancer and more than 40,290 of these women will die (ACS, 
2015).  
 Despite the seriousness of breast cancer, several studies reveal a trend in 
adherence to treatment, particularly oral medications (Volovat, Lupanscu, Ruxandra-
Volovat, & Zbranca, 2010; Ruddy, Mayer & Partridge, 2009; Ziller, et al., 2009). Only 
17 to 48% women adhere to recommendations for breast cancer treatment and just 48 to 
78% adhere to oral adjuvant hormonal treatment recommendations (Hershman, et al., 
2010; Osterberg & Blaschke, 2005; Partridge, et al., 2008; Ruddy, Mayer, & Partridge, 
2009; Ziller, et al., 2009). 
A high percentage (60-70%) of breast cancer has estrogen (ER+) or progesterone 
(PR+) positive receptors, or a combination of both. The recommended treatment for ER+ 
or PR+ breast cancer is adjuvant hormonal therapy. Despite the evidence that adjuvant 
hormonal treatment can increase the survival rate of women with breast cancer (Barrios, 
Sampaio, Vinholes & Caponero, 2009; Dowsett et al., 2010; Hershman et al., 2010;), 
adherence to this medication is suboptimal (Volovat et al., 2010; Mayer & Partridge, 
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2009; Ruddy, et al., 2009). There is a gap in literature pertaining to the knowledge and 
understanding of the factors and predictors related to the problem of adherence to 
adjuvant hormonal therapy. 
Purpose 
The purpose of this study was to examine the relationship between adherence and 
traumatic stress, depression, and symptom distress. The study also sought to determine 
whether or not non adherence is intentional or unintentional. The term intentionality was 
used to describe the participants’ desire to maintain adherence to adjuvant hormonal 
therapy during the study. This term was derived from the definition of unintentional non 
adherence, that is related to the experience of a memory lapse, forgetting, unconsciously 
stopping treatment and difficulty processing or understanding the reasons for taking the 
medication (Atkins & Fallowfield, 2006; Barber, Parsons, Clifford, Darracolt & Horne, 
2004; Lehane & McCarthy, 2007). It should be noted that the term intentionality used in 
this context is different than the definition previously used in other theories. A non-
experimental correlational study using a prediction design was used to explore the 
influence of the independent or predictor variables of traumatic stress, depression, and 
physical symptoms on the adherence to adjuvant hormonal therapy and whether this 
adherence is intentional or non-intentional. This study used a biobehavioral framework to 
examine the problem of adherence to adjuvant hormonal therapy in breast cancer 
survivors. The specific focus of the model is the Biobehavioral Model of Cancer Stress. 
This theoretical framework was selected because previous research has emphasized the 
behavioral aspect of adherence, while the psychological, spiritual, environmental and 
biological influences on health behavior outcomes, within a biobehavioral framework has 
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been unknown or overlooked (Bultz &, Carlson, 2006; DiMatteo, Lepper & Croghan, 
2000; Kirton & Morris, 2013; Moreno-Smith, Lutendorf, & Sood, 2010; Shemish et al., 
2004). This has limited the ability to fully research the problem of adherence to treatment 
in many illnesses, including breast cancer. Although this study did not directly measure 
the biological markers associated with traumatic stress, symptom distress, and depression 
the study did examine the relationship between adherence and intentionality within a 
biobehavioral framework.  
Current and past research has indicated there is a bi-directional flow of interaction 
between psychological factors, neuroendocrine, and immunological responses at the 
biologic cellular, and molecular level and each has an affect on behavioral change, 
(Andersen, Kiecolt-Glaser, & Glaser, 1994; Miller & Raison, 2008; Starkweather, et al., 
2011), modulate neurocognitive change, and psychological responses (Dantzer & Kelley, 
2007; Raghavendra, Tanga & DeLeo, 2004).  
The following research questions were used to guide the design and analysis for 
this study:  
RQ1: What is the impact of traumatic stress, depression and symptom distress on  
adherence?  
RQ2: What is the impact of traumatic stress, depression and symptom distress on  
intentional/unintentional non adherence?  
A quantitative methodology was selected as the most appropriate for this study in 
predicting adherence. A non-experimental correlational model with a predictor design 
was used to explore the influence of the predictor variables of traumatic stress, depression 
and physical symptoms/side effects on the outcome of adherence to adjuvant hormonal 
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therapy. This design tested the amount of variability each predictor variable contributed 
to the outcome of adherence. Correlational predictor research investigates the degree that 
factors influence or predict an outcome without manipulation of variables.  
Hypotheses 
The first null and alternative hypothesis addressed in the study was as follows: 
HO1: There will be no statistically significant predictors of adherence related  
to traumatic stress, depression, and symptom distress. 
HO: 1a: There will be statistically significant predictors of adherence related to 
traumatic stress, depression, and symptom distress.  
The second null and alternative hypothesis posed for the study was as follows: 
HO2: There will be no statistically significant predictors of 
intentional/unintentional non adherence related to traumatic stress, 
depression, and symptom distress. 
HO2a: There will be statistically significant predictors of 
intentional/unintentional non adherence related to traumatic stress, 
depression, and symptom distress. 
The second hypothesis asked if traumatic stress, depression, and symptom distress 
scales or subscales are predictors of intentionality to adhere or not adhere to a treatment 
regime.  
Specific Aims 
1. Determine measures of predictors in relation to the amount of variability 
they contribute to the outcome of adherence.  
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2. Examine the relationship between the predictor that contributes the most 
variability to the outcome of adherence and intentional or unintentional 
non adherence. 
Multivariate Multiple Regression Step Wise method was used to test this model. 
This method is appropriate in studies where there is more than one predictor variable and 
the goal is to determine what predictor variable contributes the most variability to the 
outcome (criterion) variable. In this study the predictor variables are traumatic stress, 
depression and symptom distress and the dependent variable is adherence behavior. 
Additional measures determined if a lack of adherence was intentional or unintentional.  
Previous studies attempting to determine predictors of adherence to adjuvant 
hormonal therapy in breast cancer report a wide variability in results that may be 
attributed to small sample size, poor conceptual definitions, lack of a gold standard for 
measurement and a lack of perspective that promotes a unified view of the problem. 
(Hershman et al., 2010; Escalada & Griffiths, 2006; Kirton & Morris, 2013). Although, 
over 50 years of research on adherence to treatment recommendations has provided 
a vast amount of literature, there are major gaps in understanding the fundamentals of 
adherence, particularly in breast cancer survivors. Overall, adherence to most medication 
is suboptimal, with an estimated average of 50% (Haynes, McDonald & Garg, 2002). 
Problems with medication adherence have the potential to cause serious consequences 
both in the clinical setting and economically for the healthcare system. Perhaps this 
indicates a new perspective of adherence is necessary, one that provides a unified view 
that considers the person and the environment.  
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In 2007, it was estimated that non adherence to medication cost the American 
healthcare system 177 billion dollars in direct and indirect healthcare costs (National 
Council on Patient Information and Education, (NCPIE, 2010). This is an important issue 
because prescription medication is one of the fastest growing segments of healthcare 
spending today. Estimates of total aggregate spending on healthcare in 2009 was 2.5 
trillion dollars; this is 17% of the gross domestic product (GDP) (Schoenman & 
Chockley, 2011). The problem of medication adherence is multifaceted, with 
consequences that are widespread, particularly in serious health conditions like cancer.  
Cancer, is rated one of the top five most expensive health conditions a person can 
experience (Schoenman & Chockley, 2011). Lack of adherence to treatment 
recommendations in serious health conditions such as cancer may be associated with 
increased hospitalizations, increased outpatient provider visits, disease progression, 
psychocsocial complications and inadequate use of healthcare resources (Hadji, 2010; 
DiMatteo & Haskard, 2006). Improved treatment adherence has been linked to better 
health outcomes in numerous diseases including breast cancer. In a meta-analysis of 63 
studies increased adherence to medical treatment reduced poor outcomes by 26% 
(DiMatteo, Giordani & Lepper, 2002). Another meta-analysis of 19,000 breast cancer 
survivors in six trials compared Tamoxifen and Aromatase Inhibitors (AIs), revealed both 
medications over a 5 year span showed a significant increase in survival rates and 
decreased recurrence (Dowsett et al., 2010). Beyond the obvious personal complications, 
financial burden and health related implications, the evidence is mounting that 
understanding predictors associated with a lack of adherence is essential for providing 
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cost effective, quality healthcare. The integration of numerous techniques for 
understanding adherence is necessary.  
Predictors commonly attributed to decreased adherence in adjuvant hormonal 
therapy for breast cancer survivors include, perceptions of poor risk to benefit ratio, low 
socioeconomic status, medication side effects, poor provider communication, emotional 
distress, knowledge deficits, psychological problems (particularly depression), memory 
issues, extreme age, and features of the healthcare system (Burgess et al., 2005; 
Chlebowski & Geller, 2006; Kimmick et al., 2009; Matthews & Cook, 2008; Partridge, 
Avorn, Wang, & Winer, 2002; Partridge, Ades, Spicer, Englander & Wickerman, 2007; 
Ruddy et al., 2009; Verma et al., 2011). Despite the identification of these predictors 
many studies have mixed and inconclusive results.  
Unfortunately, the lack of conformity in adherence terminology and measurement 
contributes to the difficulty in the comparison of studies and inability to consistently 
identify predictors of decreased adherence (Hadji, 2010; NCPIE, 2010). Further research 
is needed to overcome barriers that define and evaluate the predictor variables of 
decreased adherence to adjuvant hormonal treatment in breast cancer survivors. 
Acknowledging and examining factors that limit current adherence research is essential 
to understand this problem for improvement.  
Adherence Research Barriers 
There are several barriers that impede evidence-based research on adherence. 
First, there is a lack of a gold standard measurement either for indirect or 
direct measurement of adherence, which impedes evidence based research (NCPIE, 2010; 
DiMatteo & Haskard, 2006). Indirect measures include counting pills, electronic 
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monitoring techniques, self-report questionnaires, medication diaries and chart reviews. 
Direct measures of adherence include drug metabolite measurements of the urine 
or blood and observation of patients taking medication (Atkins & Fallowfield, 2006; 
Osterberg & Blaschke, 2005). 
Second, further research is necessary to explicate a model for research that 
includes a clearly defined multidimensional theoretical framework (DiMatteo, 2003).A 
perspective that views individuals as a unified whole in continuous mutual exchange of 
information with their environment may be applicable (Rogers, 1980; Kirton & Morris, 
2013). Treatment adherence in breast cancer survivors is an extremely complex 
phenomenon and requires a multifaceted, unifying theoretical perspective to capture the 
evidence. 	  
Third, current and past research has emphasized the behavioral aspect of 
adherence while the biological response, spiritual dimension and emotional influence on 
behavior outcome has been overlooked (Andersen, Kiecolt-Glaser & Glaser, 1994; 
DiMatteo, 2004; Glaser & Keicolt-Glaser, 2005; Moreno-Smith et al., 2010). This 
unidimensional focus has minimized the ability to adequately research adherence in 
serious illnesses such as breast cancer. This is important because research indicates there 
is a bi-directional flow of response between psychological factors and biological changes 
that are shown to affect behavior outcomes (Andersen et al., 1994; Miller & Raison, 
2008; Starkweather et al., 2011). The link between the behavioral response to perceived 
stress and biology is referred to as biobehavioral. The biobehavioral model of cancer 
stress framework for research refers to a focus on the interrelationships of psychological 
stress, behavioral and the biological processes in disease and the treatment of disease.  
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Finally, funding for medication adherence research has been inadequate over the 
last decade. In the past federal expenditures for adherence research was 3 billion dollars, 
out of a total research budget of over 18 billion dollars (NCPIE, 2010). The investment in 
adherence research for breast cancer will pay for itself through reduced healthcare costs, 
improved health outcomes and quality healthcare. 
Breast Cancer Diagnosis and Treatment 
The diagnosis of breast cancer is accompanied by information on the stage of the 
disease. This is determined by many factors including cancer growth rate and how far the 
tumor has spread. Stages I-II indicates the tumor is non-invasive, while stages III-
IV represent advanced cancer (ACS, 2009). Cancer that originates in the breast is 
referred to as primary breast cancer; however, if the cancer has spread from the primary 
site to other body organs it is defined as metastatic. 
Single and combined treatment for breast cancer includes surgery, radiation 
therapy, chemotherapy and hormonal therapy. Treatment decisions are made based on 
tumor size, stage and other factors such as age, physical health, histological grade, 
hormone receptor presence or absence and patient wishes (Palmieri & Perez, 2007). 
Although the primary treatment for breast cancer is surgery, adjuvant systemic treatment 
is frequently recommended postoperatively and is considered the standard treatment for 
early stage breast cancer (ACS, 2009; Beslija, et al, 2009; NCI, 2009). 
Adjuvant treatment is defined as additional treatment following surgery such as 
radiation, chemotherapy or hormonal therapy to prevent reoccurrence, adjuvant 
treatment may be systemic or local. Systemic therapies are administered intravenously or 
orally for patients at high risk for recurrence (Palmieri & Perez, 2007) and include neo-
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adjuvant therapy, biologic therapy, chemotherapy and hormone therapy. For the purpose 
of this study the focus was on adjuvant hormonal therapy. The two main classes of 
hormonal therapy include selective estrogen-receptor modulators (SERMs) 
and aromatase inhibitors (AI). Common AIs include anastrozole (Arimindex), 
exemestane (Aromasin), and letrozole (Femara), and the most frequently used SERM is 
Tamoxifen (Novaldex). 
Adjuvant hormonal therapy is recommended for breast cancer that is estrogen 
receptor (ER) or progesterone receptor (PR) positive after primary treatments for breast 
cancer are completed. Hormone therapy, prescribed for up to five years 
after primary cancer treatment, slows or stops the growth of breast cancer by preventing 
estrogen-dependent cancer cells from obtaining estrogen. This is important because 80% 
of breast cancers in menopausal women are ER+ or PR+ and 65% of pre-
menopausal women are ER+ or PR+ (Barrios et al., 2009). 
Significance of the Problem 
Research indicates adjuvant hormonal treatment in breast cancer survivors can 
reduce mortality by 25%, improve tumor regression and decrease tumor recurrence by 
48% (EBCTCG, 2005; Early Breast Cancer Trialist’s Collaborative Group, 2005; Barrios 
et al., 2009; Powles, Ashley, Today, Smith, & Dowsett, 2007). Despite the evidence that 
adjuvant hormonal therapy can significantly improve survival rates for women with 
breast cancer (Barrios et al., 2009; Chaterjee, 2006; Clemons & Goss, 2001; Hershman et 
al., 2010), adherence to this medication continues to be a problem (Hadji, 2010; Partridge 
et al., 2008, Ruddy et al., 2009). Numerous studies reveal that 38-55% of breast cancer 
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survivors are not adherent to adjuvant hormonal therapy within the first year (Cluze et al., 
2011; Owsu et al., 2008; Partridge et al., 2008). 
The assumption that women with breast cancer are more compliant and motivated 
to adhere to hormone treatment due to the seriousness of their illness is uncertain 
(Partridge et al., 2007; Ziller et al., 2009). The lack of clarity in measurement, definition 
and knowledge surrounding this problem, inhibits the implementation of effective 
intervention strategies that could improve patient outcomes. Today, this is particularly 
relevant since patients prefer oral cancer therapies (Hohnecker, Shah-Mehta, & Brandt, 
2010); however, research indicates the adherence to oral adjuvant hormonal therapy is 
suboptimal (Cluze et al, 2011; Hershman, et al., 2010; Ziller et al., 2009). This is a 
problem because consistent and reliable predictors of decreased adherence to adjuvant 
hormonal therapy have not been identified (Volovat et al, 2010).  
Cancer and Stress 
The primary focus of biomedical care is the treatment of physical health problems 
associated with cancer, while emotional, environmental, spiritual or psychological issues 
are frequently neglected (Lutofsky et al., 2004). The diagnosis of cancer has been 
considered one of the most stressful events that can occur in a person’s life. The 
American Psychiatric Association (APA) has determined that being diagnosed with 
cancer or any life threatening illness meets criteria for a traumatic event (APA, 2013). 
Medical problems may be experienced as traumatic for some individuals leading to 
numerous psychological, behavioral and physiological changes that can negatively 
impact normal functioning in the short and long term (Miller, Ancoli-Israel, Bower, 
Capuron & Irwin, 2008; Mundy & Baum, 2004). The psychological effects for breast 
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cancer survivors can be life-altering because of the fear of death, treatment side effects, 
uncertainty and concerns about recurrence.  
Many studies indicate that patients’ experience depression, anxiety, symptom 
distress and post traumatic stress disorder (PTSD) symptoms after the diagnosis of cancer 
and especially during cancer treatment (Andersen et al., 1994; Andrykowski, Lykins & 
Floyd, 2008; Carlson, Groff, Maciejewski & Bultz, 2010; Holland & Bultz, 2010; Linden 
& Siu, 2009; NCI, 2009; Vodermaier et al., 2009). The experience of being diagnosed 
and treated for breast cancer can elicit a traumatic stress reaction similar to PTSD. These 
symptoms can manifest as fear, hopelessness, helplessness, depression, anxiety, 
insomnia, nightmares, fears of reoccurrence, irritability, avoidance, intrusive thoughts, 
anger, hyperarousal, dissociation and intermittent memory loss (APA, 2013; 
Kwekkeboom & Seng, 2002; NCI, 2009).  
For this study the traumatic stress reaction was defined as the response to a 
traumatic event that is sudden, shocking and uncontrollable, producing extreme fear, 
involving a threat to life that may predispose an individual to PTSD symptoms (NCI, 
2009; Koopman et al., 2002). In the diagnostic statistical manual V (DSM V), PTSD is 
classified as an anxiety disorder with co-occurrence rates that are high (APA, 2013). Co-
occurrence is defined as the presence of two diagnoses at the same time that are not 
related. Although, a high percentage of individuals have a co-occurrence of PTSD and 
depression these are considered two separate diagnoses (APA, 2013). Overall, cancer 
survivors experience depression rates that are four times higher than the average 
population (AHRQ, 2002). 
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The traumatic stress and depression that can be elicited by the diagnosis and 
treatment of breast cancer may affect the ability to initiate or maintain positive health 
behaviors such as adherence to medication (Andersen et al., 1994; Andersen, 2010; 
DiMatteo et al., 2000; Holland & Bultz, 2010; NCI, 2009; Vranceanu et al., 2008). This 
may occur due to the combination of psychological responses and biological reactions 
associated with traumatic stress experienced following the diagnosis and treatment of 
breast cancer. Untreated traumatic stress can cause many different changes that can affect 
normal functioning of the body and mind including cognitive deficits, intrusive thoughts, 
emotional numbing, depression, loss of appetite, disruption of sleep, lack of motivation, 
decreased energy, symptom distress and behavioral-cognitive avoidance (Bush, 2007; 
NCI, 2009; Shelby, Golden-Kreutz, & Andersen, 2008). The single or combined effects 
of these symptoms may be connected to a phenomenon known as unintentional or 
intentional non adherence.  
The definition of unintentional non adherence has been related to the experience 
of a memory lapse, forgetting, unconsciously stopping treatment and difficulty processing 
or understanding the information provided about a medication (Atkins & Fallowfield, 
2006). Other definitions of unintentional non adherence include difficulty understanding 
the complexity of a medication regimen or not understanding the reasons for taking the 
medication (Barber, Parsons, Clifford, Darracolt & Horne, 2004; Lehane & McCarthy, 
2007). Intentional non adherence is related to a patient making a conscious decision not 
to take a medication due to side effects, cost, lack of insurance, education, or 
environmental factors (Atkins & Fallowfield, 2006; Kirton & Morris, 2013).  
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The prevalence of emotional responses such as PTSD symptoms, mood 
disturbance including anxiety and cancer depression in breast cancer survivors is well 
documented (Badger, Segrin, Dorros, Meek & Lopez, 2007; Burgess et al., 2005; Bush, 
2007; Mundy & Baum, 2004; Guervich, Devins & Rodin, 2002). Frequently, these 
symptoms are not recognized during the breast cancer diagnosis or treatment process and 
factors that can predict emotional responses to a serious illness are not well studied 
(Matthews & Cook, 2008). There are various stages of adjustment an individual can 
experience when coping with the diagnosis and treatment of a serious illness. Traumatic 
stress symptoms and depression may occur at different times during the cancer trajectory 
(Miakowski, Shockney, & Chlebowski, 2007; Sheldon, Swanson, Dolce, Marsh & 
Summers, 2008). These symptoms are associated with a lower quality of life (Anderson 
et al., 1994; Karokovan-Celik et al., 2010) and may increase physical symptoms, side 
effects, behavioral changes, and health behavior outcomes such as adherence (Holland & 
Alici, 2010; DiMatteo et al., 2000).  
Despite this evidence, cancer patients are not being screened for emotional 
responses such as; depression or PTSD symptoms on a regular basis and 
frequently healthcare professional’s rate emotional distress levels lower than the patient 
reports (Carlson et al., 2010; Holland Vitek, Rosenzweig & Stollings, 2007; Jacobsen et 
al., 2004). This may be due to a unidimensional focus of patient care, knowledge gaps 
and lack of educational preparation. The term distress is used to describe emotional and 




The National Comprehensive Cancer Network (NCCN) define distress as the 
unpleasant experience of an emotional, psychological, social, or spiritual nature that 
interferes with the ability to cope with a cancer diagnosis and treatment, that is on a 
continuum from normal vulnerability, sadness and fear to problems that are disabling 
such as depression, anxiety, panic and feelings of isolation (Holland & Bultz, 2010). 
Depression in cancer can be defined as a feeling of sadness most of the day that lasts 
longer than 2 weeks and is accompanied by tiredness, insomnia, worthlessness and poor 
concentration. This type of depression related to cancer is referred to as reactive 
depression and is different than the psychiatric diagnosis of major depressive disorder 
(MDD), although may progress to MDD if unrecognized (NCI, 2009; APA, 2013). 
Associated reactions can range from normal to extreme dysfunction that may impair 
normal functioning in activities of daily living (Karokovan-Celik et al., 2010).  
  Symptom distress, experienced by an individual diagnosed with breast cancer 
may be related to the treatment, disease process, and the emotional response to stress. 
The combination of these factors may exacerbate the psychological distress related to this 
disease process (Moreno-Smith et al., 2010). For this study the construct of symptom 
distress was defined as the degree of emotional and psychological discomfort an 
individual experiences as self reported by the patient. 
  The proposed research examined the predictors of adherence to adjuvant 
hormonal therapy in breast cancer survivors using a bio-behavioral framework specific to 
cancer stress. Although this study did not directly measure the biological markers 
associated with adherence, it did examine behavioral and psychological responses 
associated with traumatic stress, symptom distress and depression from a biobehavioral 
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perspective. To my knowledge this is the first study to apply a bio-behavioral theoretical 
framework to research predictors that affect adherence to adjuvant hormonal therapy in 
breast cancer survivors. This study will provide knowledge that will guide future research 
and potentially develop interventions for evidence based practice to improve patient care.  
Research Contribution 
The long term goals of this research are first, to improve routine screening for 
traumatic stress (PTSD) symptoms, depression and symptom distress in breast cancer 
survivors early in the treatment process through education; second, to improve healthcare 
and quality of life for breast cancer survivors by promoting this evidence in clinical 
practice; third, to explore a multidimensional theoretical framework for adherence 
research that is specific to cancer stress. The results of these hypotheses were used to 
determine if a relationship exists between decreased adherence to adjuvant hormonal 
therapy and the predictor variables of traumatic stress, depression and symptom distress. 
Further, to examine if decreased adherence is intentional or unintentional. Although, 
correlational research does not provide a causal relationship between variables, the results 
can be used to further study the biobehavioral mechanisms of cancer stress on health 
behavior outcomes. This research will contribute to the understanding of non adherence 
to adjuvant hormonal therapy in breast cancer survivors and improve knowledge of 





Adherence to adjuvant hormonal therapy in breast cancer survivors has not been 
sufficiently studied. Results from many large clinical studies on adherence are based 
primarily on self-report measures and often the reasons provided for discontinuation are 
ambiguous (Verma Madarnas, Sehdev, Martin, & Bajcar, 2011). The following is a 
review of theoretical models that have been used to study health behavior outcomes that 
will provide a perspective on the multidimensional nature of adherence. Additionally, the 
following literature review will explore the current research available, the importance of 
the problem and the complexity related to this issue.  
Research results indicate adjuvant hormonal therapy is efficacious for improving 
survival outcomes in women with breast cancer. In a study of 30,000 women with 
estrogen receptor positive (ER+) breast cancer, results indicated the use of tamoxifen for 
five years reduced the 10-year mortality rate by 25% (EBCTCG, 2005). Other studies 
indicate women with ER+ tumors have a 48% reduction in tumor recurrence with 
tamoxifen (Powles et al., 2007). Since 1970, the use of tamoxifen has significantly 
improved the survival rate of women with breast cancer.  
Clinical benefits of adjuvant hormonal therapy is obvious and further supported 
by studies of third generation aromatase inhibitors (AIs). In one study of 907 women 
using a third generation AI (letrozole) findings revealed greater tumor regressions and 
decreased recurrence rate compared to tamoxifen (Mouridesen et al., 2003). Many 
different studies indicate that AIs may be more effective than tamoxifen as adjuvant 
treatment for breast cancer. A large study with 9,366 postmenopausal women compared 
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anastrozole,, a third generation AI to tamoxifen. Results showed there was less 
recurrence and increased survival rates for subjects using anastrozole with ER+ 
disease (Howell et al., 2005).  
Longitudinal studies comparing AIs and tamoxifen reveal the same findings of the 
possible superior ability of AIs to decrease tumor recurrence, improve disease free 
survival rates and offer higher response rates in the treatment of ER+ and Human 
Epidermal Growth Receptor positive (HER2+) breast cancer (Dowsett et al., 2010; 
Mouridsen, Globbie-Hurdee, & Goldhirsch, 2009; Smith, Dowsett & Ebbs, 2005). 
HER2+ indicates the presence of the protein human epidermal growth factor, this protein 
promotes the growth of cancer cells and is considered an aggressive cancer (NCI, 2009).  
Tamoxifen has been the standard anti-estrogen treatment for hormone positive, 
early stage breast cancer for over 30 years. Although tamoxifen has been shown to be 
highly effective various risks are associated with taking tamoxifen including higher risk 
for cervical cancer, thrombo-embolism, hot flashes, and depression (Serkalme, Silliman, 
& Lash, 2001; Ziller et al., 2009). Tamoxifen use also presents another issue, metastatic 
breast cancer exhibiting a higher expression of HER2+ can develop a resistance to 
tamoxifen over time, and there may be problems with relapse and distant recurrences that 
can be fatal (Chlebowski & Geller, 2006). 
Evidence suggests AIs have greater effectiveness and may be better tolerated with 
respect to certain side effects compared to tamoxifen (Dowsett et al., 2010; Kesisis, 
Makris & Miles, 2009). In a Big International Group (BIG) study, 8,028 postmenopausal 
women with HR+ early breast cancer received random assignment to tamoxifen or an AI. 
After 36 months, data indicated there was a significantly greater reduction of 19% in 
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recurrence compared with tamoxifen (Coates et al., 2007). Current recommendations 
from the American Society of Clinical Oncology and other respected cancer 
organizations recommend first line adjuvant therapy with AIs for postmenopausal women 
that are ER+ (Goldhirsch et al., 2007; Kesisis, Makris, & Miles, 2009). Currently, 
recommendation for premenopausal women with ER+ breast cancer continues to be 
tamoxifen due to early menopausal syndrome (NCI, 2009). Despite evidence that 
adjuvant hormonal therapy is beneficial for breast cancer survivors, there are numerous 
side effects associated with these medications. 
AIs and tamoxifen have a side effect profile that may prevent adherence to these 
medications. The adjuvant hormones tamoxifen and AIs, increase menopausal symptoms 
or cause these symptoms to occur regardless of age. Tamoxifen increases the risk of 
thrombosis and endometrial cancer, and AIs increase the risk of osteoporosis and cause 
arthralgia (Kesisis et al., 2009). Some of these side effects may contribute to the problem 
of decreased adherence (Amir, Seruga, Niraula, Carlsson & Ocana, 2011). Additional 
research is necessary to identify the role of side effects as a predictor of decreased 
adherence to adjuvant hormonal therapy.  
Adherence Factors 
In a large study, of 8,761 women with early stage breast cancer prescribed 
adjuvant hormonal therapy, 38–40% of patients did not maintain adherence within the 
first year of treatment (Hershman et al., 2010). This study utilized a large de-
identified cancer registry database. Clinical trials report higher adherence rates for 
adjuvant hormonal therapy (Chlebowski & Geller, 2006); this suggests that real life 
values for adherence are lower than assumed. In another study, 131 women with breast 
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cancer receiving adjuvant hormonal therapy, self- report revealed 55% of patients had 
decreased adherence to treatment, as measured by interviews and completing 
standardized psychological measures (Atkins & Fallowfield, 2006). Adherence to 
adjuvant hormonal treatment in breast cancer appears to be consistent with the trend of a 
lack of adherence to medication in general. Studies have shown that 23-60% of women 
receiving adjuvant hormonal treatment, discontinue the drug before the course of 
treatment is completed (Owsu et al., 2008; Partridge et al., 2008). Although, women may 
experience physical side effects they may not report symptoms, and may be less likely to 
report emotional difficulties related to the overall experience of breast cancer.  
Atkins and Fallowfield (2006) suggest that non adherence can be classed into two 
different groups, either intentional non adherence or unintentional non adherence. Factors 
associated with intentional non adherence include lack of education, cost versus benefit is 
not obvious, physical side effects, and psychological readiness in accepting the disease 
process (Elwyn, Edwards & Britton, 2003). Factors associated with unintentional non 
adherence may include neurocognitive deficits related to traumatic stress, anxiety, 
depression, medication regimen complexity, sedating effects, psychological readiness and 
emotional inability to provide self-care (Andersen, Golden-Kreutz, Emery, Thiel, 2008; 
DiMatteo, Haskard, Summer, & Williams, 2007). Rogers (1980) in the Science of 
Unitary Human Beings, postulates that individuals make choices to determine the 
changes they desire to make in their lives. This concept within the theory of Science of 
Unitary Human Being is referred to as Power. The definition of this concept of Power is 
being aware of what one is choosing to change and making this decision with 
intentionality (Barrett, 2000; Kirton & Morris, 2013). Self-efficacy and the ability to 
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follow through with adherence may also be considered in relation to the concept of 
Power. The intention to change is related to the dynamic interaction and mutual response 
of the person with their environment.  
Emotional Factors 
Research indicates 15–32% of breast cancer survivors experience traumatic stress 
possibly leading to PTSD symptoms, depression, and anxiety (Bush, 2007, NCI, 2009; 
Mundy & Baum, 2004). In a study of 222 women with early stage breast cancer 50% 
experienced depression in the first year and up to 25% in the second year following 
diagnosis (Burgess et al., 2005; Caplette-Gingras & Savard, 2008). This suggests a larger 
number of breast cancer survivors have experienced depression than previously 
suspected. PTSD symptoms have been seen in 25-50% of cancer survivors (Guervich et 
al., 2002; NCI, 2009). Traumatic stress, anxiety and depression can impair the ability to 
process information, affect memory, impair concentration and decrease the ability to 
adhere to treatment. Many studies have shown women with breast cancer taking 
hormonal treatment (i.e., tamoxifen and AIs) have missed doses because they forgot 
medication (Bush, 2007; Atkins & Fallowfield, 2006; Murthy, Bharia & Sarin, 2002). 
This problem may be associated with unintentional non adherence that is not related to a 
conscious awareness or intentional decision to stop the adjuvant hormonal therapy.  
Conceptual Analysis of Adherence 
Analysis of the concept of adherence is an essential first step in understanding its’ 
relationship to prescribed hormone therapy in the cancer setting. Adherence—a concept 
of considerable importance to a variety of professional disciplines—is multidimensional 
and includes intangible actions, intentions, and emotions (DiMatteo, 2004; Ruddy et al., 
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2009; Partridge et al., 2008; Walker & Avant, 2005). Although agreement exists around 
its importance, definition lacks consensus because many dimensions of adherence are not 
directly observable. To understand the problem of adherence to adjuvant hormonal 
therapy, a literature search using multiple databases was conducted using the key terms: 
adherence, concordance, compliance, persistence, self-efficacy, self-care, medication, 
health behavior, aromatase inhibitors, endocrine therapy, hormone therapy and adjuvant 
therapy, both singly and in combination. 
Clinicians and researchers have struggled to differentiate adherence from other 
terms such as adherence, compliance, concordance, persistence, which are frequently 
used interchangeably (DiMatteo, 2004). Adherence focuses primarily on the collaborative 
relationship between patient and provider during the treatment decision process, yet 
“compliance” implies a lack of shared decision-making and often describes patients 
decision to conform to healthcare recommendations.  
There has been debate over the years about the paternalistic nature of the term, 
“compliance” (Chatterjee, 2006; Murphy & Cannales, 2001). Concordance is 
differentiated from the concept of adherence because the definition indicates an equal 
partnership. Unfortunately, equality in patient/provider relationships does not always 
occur in the current biomedical model of care. Persistence is a term used to describe 
medication use or prescription refills over a prolonged time (Bissonnette, 2008; 
DiMatteo, 2004; Kimmick et al., 2009). The lack of consensus on the use of these terms 
has led to the difficulty in standardization and measurement of the concept (Bissonnette, 
2008; Cohen, 2009). 
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Adherence is the most commonly used term today and is described as the ability 
and desire to maintain a prescribed treatment plan that is recommended by a healthcare 
provider over time (Haynes, et al., 2004). Other authors have defined adherence by 
including the words persistence, active collaboration, and involvement with others to 
achieve a desired behavior (Benner et al., 2002; Chatterjee, 2006; Carpenter, 2005). 
Different uses of the concept adherence include an individual’s ability to follow 
instructions and collaborate with one another to reach a mutually agreed upon health 
promoting behavior. 
When patients do not follow directions to a prescribed regimen of care, healthcare 
professionals often refer to this behavior as a lack of adherence. One might assume 
adherence and a lack of adherence are opposites; however, the definition of 
this concept is complex and multifaceted. During the course of treatment, 
an individual may remain on medication for a specified time, then stop entirely and 
restart again. There may be many different reasons an individual does not follow through 
with the decision to complete a regimen of prescribed medication. Although, adherence 
has been defined by the World Health Organization (WHO), as the extent to which an 
individual follows medical instructions” (Osterberg & Blascke, 2005), lack of adherence 
to treatment can take many forms including being late or canceling appointments, and 
prematurely terminating treatment. These definitions also do not take into account that a 
patient may not use a medication for a valid reason such as side effects, emotional 
problems, trauma, environmental factors, financial hardship or lack of understanding of 
the disease.  
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Adherence Definition Summary 
Adherence in the literature is defined as the ability and desire to sustain a 
prescribed treatment plan recommended by a healthcare provider over time (Haynes et 
al., 2005; DiMatteo, 2004). Although the definition of adherence is complex and the 
concept can take many forms, a standardized definition is essential for research. For this 
study, adherence will be defined using the accepted World Health Organizations’ 
definition that states, “adherence is the extent to which an individual follows medical 
instructions” (Osterberg & Blascke, 2005).  
Adherence has been studied using many different theoretical frameworks. Despite 
the use of many theories to study health behavior outcomes, there has not been a chosen 
theory to emerge that has been able to fully explain adherence.  
Conceptual Theoretical Framework 
Theories and conceptual frameworks provide organizing structures, connections 
between concepts, and research direction that aid in understanding the concept of 
adherence. Evidence-based interventions require the use of an appropriate theoretical 
framework to effectively explore the concept of adherence. Many theories have 
incorporated adherence in relation to the characteristics of the patients’ social 
environment, perceived susceptibility, treatment regimens, health beliefs, and 
communication in patient/provider relationship, such as the Health Belief Model 
(DiMatteo, 2007; Rosenstock, Strecher & Becker, 1994), social cognition theory (SCT) 
(Bandura, 1997), theory of planned behavior (TPB) (Aizen, 1991), Prochaska’s 
transtheoretical model (TTM) of change (Prochaska, DiClemente & Norcross, 1992), 
common sense model/self regulatory model (Leventhal, Leventhal, & Contrada, 1998) 
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and biobehavioral model of cancer stress (BMCS) (Andersen et al., 1994). These 
theorists agree that significant determinants of adherence include understanding of the 
treatment goals, assessment of risk versus benefit and motivation to change (Burns, 2009; 
Hadji, 2010; Partridge et al., 2002; Ruddy et al., 2009). Despite the utility of theoretical 
underpinnings, theoretically based adherence research is the exception rather than the 
rule. 
Over the years, numerous theories have attempted to describe health 
behavior. The health behavior model (HBM) is one of the most widely used 
psychological theories. The HBM attempts to explain health behaviors in relation to 
attitudes and belief, based on the concepts and perceptions of disease susceptibility, 
severity, benefits, barriers, action, and self-efficacy (Rosenstock et al., 1994). Bandura 
(1986), in his social cognitive theory (SCT), suggested that a person’s mind constructs 
their reality based on attitudes, beliefs, experiences and feedback from the environment. 
Self-efficacy is an essential part of HBM and SCT and refers to the ability of one to 
recognize, learn, understand and replicate a success from past experiences. Although the 
HBM theory incorporates many of the elements of SCT, neither one specifically 
addresses the difficulties presented by a problem such as, environmental influences, 
financial hardship or serious emotional difficulties. Aizen (1991) theory of planned 
behavior (TPB) proposes that intention, attitude, social norms and perceived control are 
the greatest predictors of health behavior. This theory incorporates the notion that the 
idea of personal control may have an overriding influence on one’s health behavior. More 
importantly, TPB does not address emotional regulation, therefore does not 
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address variables such as; threat, fear, mood, and negative feelings that may limit the 
ability to adhere to treatment. 
Several other theories that come closer to a good fit for the study of adherence to 
treatment in breast cancer include Levanthal, Levanthal, and Contrada’s (1998) common 
sense model/self- regulatory theory (CSM) and Prochaska’s transtheoretical model 
(TTM) of change. In the CSM model, health related behaviors are heavily influenced by a 
person’s own ideology or representations of an illness. Further, five themes and questions 
that patients may ask themselves are: a) Identity: what is it? b) Time line: how long will it 
last? c) Cause: what is the purpose of this illness? d) Consequences: how will it affect 
me? In the CSM theory, the ability of participants to be coherent of abstract ideas and 
apply them to existing symptoms of the illness is essential. Emotional responses or 
biological influences that may affect aspects of decision-making skills are not addressed 
in Leventhal’s common sense model.  
The transtheoretical model (TTM) of change is a model that includes 
several components of other theories including, self-efficacy, motivation, decisional 
balance (the pros and cons of changing behavior), social influences, cultural influence, 
and environmental factors that influence or present a setting that promotes problem 
behavior (Prochaska et al., 1994). The TTM theory of change acknowledges personal 
motivation to change in relation to psychological and sociological influences that impede 
one’s ability to change health behaviors. This theory presents a circular rather than linear 
perspective and proposes that evolution is a process that is active and in a continual state 
of flux. The TTM uses four theoretical constructs that include stages of 
change, decisional balance, self-efficacy and the process of change over time 
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(O’Donohue & Levensky, 2006; Prochaska et al., 1994). Although TTM is a holistic 
theory, it lacks the ability to address unknown problems, such as unconscious reactions to 
acute stress or trauma related to the diagnosis of a life threatening disease. 
Unfortunately, the TTM does not provide a visible relationship between stress and the 
psychological factors of trauma, depression and the biological influences that may affect 
adherence. 
The current theoretical models of adherence presented do not have the ability to 
fully explore the experience of coping with a life threatening illness, such as breast 
cancer. Psychological responses to stress associated with a serious illness can evoke 
emotional reactions and may include, symptoms of anxiety, panic, sadness, depression 
and insomnia. (Andersen, 2002; Mundy & Baum, 2004) These symptoms are frequently 
missed due to a primary focus on the physical treatment of breast cancer or a lack of 
knowledge. To fully explore adherence to adjuvant hormonal therapy a multifaceted 
theory is essential.  
Proposed Theoretical Framework 
The Biobehavioral Model of Cancer Stress (BMCS) provides a multidimensional 
theoretical framework that is specific to the stress experienced in cancer. The BMCS 
model posits the stress of cancer may produce psychological and behavioral responses 
that initiate mechanisms that influence biological processes and possibly health behavior 
outcomes (Andersen et al., 1994). An example of this response is the traumatic stress 
reaction defined in this study, as the response to a traumatic event that is sudden, 
shocking and uncontrollable, that may predispose an individual to PTSD symptoms, 
depression and may exacerbate symptom distress. The following page displays the 
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Biobehavioral Model of Cancer Stress by Andersen et al (1994). This model 
demonstrates the interactions between the diagnosis and treatment of cancer in response 
to stress created by the disease process. Figure 1 displays the Biobehavioral Model of 




Figure 1. Biobehavioral Model of Cancer Stress (Andersen et al., 1994). 
The traumatic stress response associated with cancer may increase the negative 
symptoms associated with cancer treatment and if left untreated has the potential to 
introduce biobehavioral consequences. These include bi-directional influences on 
biological pathways such as stress induced immunological and neuroendocrine responses 
that increase cytokines, decrease oxytocin, decrease dopamine, decrease serotonin, 
increase cortisol levels, and promote stimulation of the autonomic nervous system 
(Armaiz-Pena, Lutgendorf, Cole & Sood, 2009; Het, Ramlow & Wolf, 2005; Elzinga, 
Bakker, & Bremner, 2005). The neurotransmitters serotonin, norepenephrine and 
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dopamine are important in mood regulation and identified with depression and traumatic 
stress reactions.  
Traumatic stress has been shown to activate the inflammatory response of the 
body by increasing cytokines and stimulating their signaling pathways (Dantzer & 
Kelley, 2007; Raison, Capuron & Miller, 2006). Cytokines are activated during the 
inflammatory response and have been shown to deplete tryptophan, the primary precursor 
for serotonin associated with depression in cancer (Capuron, Raison & Musselman, 2003; 
Eisenberger & Lieberman, 2004; Miller et al., 2008). Cytokines have also been associated 
with an increase in corticotropin releasing hormone (CRH), an important regulator of the 
hypothalamic-pituitary-adrenal (HPA) axis (Plotnikoff, Faith, Murgo & Good, 2007), 
increased CRH has been linked to depression.  
Acute and chronic stress appears to activate the biological and psychological 
systems in a simultaneous manner. Emotional responses related to a perceived 
threat cause reactions in the central nervous system (CNS) including physiological and 
chemical changes due to the release of inflammatory cytokines and hormones (Armaiz-
Paz, Lutgendorf, Cole, & Sood, 2009; Miller et al., 2008). The endocrine system is 
responsible for the release of hormones that primarily affect the hypothalamic-pituitary-
thyroid axis, the hypothalamic growth hormone axis and the hypothalamic-pituitary-axis 
(HPA) (Lutgendorf, Sood & Antoni, 2010).  
The HPA axis has been most often studied in relation to stress responses in 
humans and has a fundamental role in the stress trauma reaction. Research indicates 
individuals that experience stress related trauma exhibit HPA axis deregulation and 
abnormal endocrine functioning including, hyper-secretion of cortical and 
 
 30 
adrenocorticotropic hormone, pituitary and adrenal hypertrophy (Andersen, 2002). HPA 
axis function has a role in the production of neurotransmitters such as serotonin, 
epenephrine and dopamine; these neurotransmitters are associated with mood changes 
and cognitive functioning. HPA imbalance has been linked to traumatic stress, anxiety, 
depression and memory problems (Southwick, Rasmusson, Barron, & Arsten, 2005; Stahl 
& Wise, 2008).  
Neuroendocrine research in cancer patients has shown subjects display the same 
dysfunction of the HPA axis that is present in patients with depression and anxiety 
disorders (Andersen, 2002; Simeon et al., 2007). During the neuroendocrine system 
response to stress, there are parallel changes in mood, attention, memory, task 
performance and the ability to solve problems. Mood disorders, such as the trauma stress 
reaction and especially depression are associated with these symptoms and consistently 
associated with decreased adherence to treatment in cancer (Burgess, 2005, 2003; 
DiMatteo, 2000; Onitilo, Nietert & Egede, 2006; Spiegel & Giese-Davis, 2003). 
In a study of 131 breast cancer survivors receiving hormonal treatment a total of 
55% of these women reported being non-adherent, most of these non-adherers (83.7%) 
reported this non adherence as related to a memory problem. This outcome was not 
attributed to a decline in memory due to the aging process (Atkins & Fallowfield, 2006). 
The experiences of traumatic stress and depression have biological effects that include 
increased cytokine activation and adrenal gland stimulation causing the release of 
glucocorticoids, resulting in increased cortisol and norepenphrine levels, this response 
can decrease hippocampal functioning (Maier & Watkins, 2003; Szabo, Gould & Manji, 
2004). The hippocampus is critical in learning and short term memory (Stahl &Wise, 
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2008). Immune cytokine administration with laboratory animals has been shown to affect 
cognitive processes, behavior and long term affects in the hippocampus that cause 
memory problems (Maier, 2003; Monje, Toda & Palmer, 2003).  
 Immunological responses to inflammatory reactions including the release of 
cytokines and tumor necrosis factor have been shown to precipitate or exacerbate 
depression (Musselman, 2001). Studies with magnetic imaging resonance (MRI) indicate 
cytokines affect a part of the brain, the dorsal area of anterior cingulated cortex (dACC), 
that responds to a traumatic stress reaction and regulation of coping in response to a 
serious perceived threat (Capuron, et al., 2005; Eisenberger & Lieberman, 2004). 
Research suggests that the inflammatory response may be associated with the 
pathophysiology of neurocognitive deficits in cancer patients (Maier, 2003). 
The relationship between psychological processes, oncology, biology, neuro-
endocrinology, and the pathophysiological pathways are known to be involved in the 
regulation of behavioral responses in cancer survivors. These biological and 
psychological correlates may provide an explanation for unintentional or intentional 
non adherence in some breast cancer survivors. Research indicates that traumatic stress is 
correlated with psychological distress, autonomic nervous system changes, immune 
functioning and endocrine involvement (APA, 2013; Guervich et al., 2002). These 
biological changes associated with the immune and endocrine systems can 
affect progression of disease, behavioral alterations, (traumatic stress and depression) 
symptom distress, survival, quality of life, and behavior outcome decisions (Andersen, et 
al., 1994; Antoni et al., 2006; Armaiz-Pena et al., 2010). On the following page is an 
adapted version of Andersen’s (1994) Biobehavioral Model of Cancer Stress. It displays 
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the traumatic stress response and the numerous biobehavioral interactions that have been 
discussed. Figure 2 displays an adapted version of the Biobehavioral Model of Cancer 
Stress for this study. 
 
 Figure 2. Adapted from Andersens’(1994) Biobehavioral Model of Cancer Stress  
 
The diagnosis and treatment of breast cancer is considered a life threatening event 
(APA, 2013). The experience of traumatic stress occurs in response to the perception of a 
serious threat that occurs suddenly and is perceived as uncontrollable. Traumatic stress 
may predispose an individual to PTSD symptoms that include nightmares, intrusive 
thoughts, avoidance, detachment, hyper arousal, decreased concentration, irritability and 
insomnia (Guervich et al., 2002; NCI, 2009). Traumatic stress is differentiated from 
transient psychological distress by the persistence of the symptoms beyond the 
termination of the stressor. A traumatic stress reaction may progress to a biological and 
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psychological response. Psychological distress is defined as a span of emotions that are 
experienced during the diagnosis and treatment of cancer (Holland & Bultz, 2010). The 
recommendation from NCI (2011) posits that psychological distress be thought of as 
anxiety and depression.  
The stress induced psychological and pathophysiological response to the 
diagnosis and treatment of breast cancer may introduce many barriers related to 
maintaining adherence to adjuvant hormonal therapy that are not due to health beliefs, 
motivation or self-efficacy. Research indicates the experience of traumatic stress and 
depression related to a life threatening illness impairs cognitive functioning 
including focus, memory, concentration, hearing and decreases motivation that ultimately 
affect the ability to adhere to treatment (Bultz &, Carlson, 2006; DiMatteo et al., 2000; 
Shemish et al., 2004).  
Early trauma research by Christenson (1984; 1992) describes the experience, 
when an individual feels threatened or traumatized, as a significant narrowing of 
consciousness with the ability to focus and concentrate is diminished. This narrowing of 
consciousness can evolve into a state of amnesia for parts of the traumatic event. The 
definition of PTSD in the DSM IV recognizes that trauma can lead to extreme issues with 
retention, learning, and memory (APA, 2013). An individual may not remember to take 
medication due to a traumatic stress reaction, depression or symptom distress that 
biologically affects the ability to process information and may be related to unintentional 
or intentional non adherence. 
The pathophysiologic pathways and the bi-directional interaction between the 
neuroendocrine and the immunological systems are associated with the regulation of 
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psychological behavior, and therefore may mediate behavioral responses in cancer 
survivors. Behavioral alterations include outcomes and responses such as depression, 
symptom distress, anxiety, insomnia and cognitive changes that contribute to the 
behavioral health outcome of decreased adherence to medication. Research  
indicates this bidirectional flow of influence between reactions to an environmental 
stressor such as breast cancer and biological processes can precipitate or exacerbate a 
traumatic stress reaction leading to PTSD symptoms, depression, anxiety, increased 
inflammation, increased pain, and increase recurrence of cancer through tumorigenesis 
(Antoni et al., 2006; Armaiz-Paz et al., 2009; Dantzer & Kelley, 2007; Lutgendorf et al., 
2010; Miller et al., 2008; Raison et al., 2006). These are examples of the biobehavioral 
consequences that can occur if emotional and psychological stress responses associated 
with breast cancer are not recognized and effectively managed. 
Additionally, the treatment process for breast cancer has biological and 
psychological effects that can cause negative symptoms including increased pain, nausea, 
fatigue, impaired cognitive functioning, emotional distress, anxiety, depression and 
insomnia (Hershman et al., 2010). Increasing evidence has shown that psychological and 
biological effects of cancer and treatment are connected. Interventions that include an 
integrative paradigm of patient care with physical, environmental and psychological 
support may decrease the possible biobehavioral consequences of stress (Andersen, 2010; 
McCain, Gray, Walter, & Robins et al., 2005).  
The connection between the brain, psychological mood states, symptom distress 
and biological changes that affect behavior outcomes related to a serious illness is not 
well understood and requires further exploration. The use of a theoretical framework that 
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proposes a connection between the behavioral, psychological, spiritual and biological 
processes in the body provides a unifying framework to research adherence in breast 
cancer survivors.  
The Biobehavioral Model of Cancer Stress (BMCS) offers a multidimensional 
approach to research the problem of adherence to adjuvant hormonal therapy in breast 
cancer survivors. This framework offers a comprehensive explanation of the mechanisms 
for psychological, environmental and behavioral responses that affect biological 
processes in response to traumatic stress, depression , physical symptoms and ultimately 
health behavior outcomes (Andersen et al., 1994; Golden-Kreutz et al., 2005). Past and 
present research supports the biobehavioral theoretical framework and the integrative 
paradigm of psychological, biological and behavioral changes that occur through the 
diagnosis and treatment of the disease process (Andersen et al., 1994; Anderson, 2010; 
Lutgendorf et al., 2010; McDonald et al., 2005; Miller et al., 2008).  
Implications for Nursing 
A comprehensive understanding of adherence in breast cancer survivors requires a 
different perspective of nursing care. A perspective that is multifaceted and views the 
person as a unified whole that is not separate from their environment. Rogers’ Science of 
Unitary Human Beings (SUHB) proposes that human beings are a unified whole field of 
energy that is in continuous mutual interaction and exchange of information with the 
environment. The emphasis of the SUHB is on the integrality of human environment field 
phenomena. This paradigm introduces the idea of the irreducible nature of individuals as 
energy fields, different from the sum of their parts and integral with their respective 
environmental fields, this concept differentiates the nurse and identifies nursings’ focus 
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(Rogers, 1970). Considering this fundamental concept, the energy field of a person will 
change in relation to their environment, therefore the nurse is part of the healing potential 
of the environmental field, This indicates a level of responsibility for the nurse’s 
awareness and intention of his/her healing potential within the environmental field.  
The primary concepts of the SUHB are energy fields, openness, pattern, 
organization, pandimensionality, and homeodynamics (resonancy, helicy, integrality). 
Energy fields are the “fundamental unit” for both the living and nonliving and are two 
types, human and environmental (Barrett, 2000). Both human energy fields and 
environmental energy fields are irreducible wholes that do not “have” energy fields, 
rather they “are” energy fields. Also, within this framework these fields are not a 
summation of other fields such as biological, physical, social or psychological. Rogers 
(1992) makes it explicit that humans are more than the sum of their parts and cannot be 
understood by merely having the knowledge of their parts. Human energy fields are 
integral with environmental fields and are in a continuous interaction and exchange of 
energy.  
The open system concept of this framework offers that energy fields are open, 
dynamic, infinite and continuously interacting with one another. Within this open system 
change is continuous and nonlinear. Causality is not considered an option within the open 
system. Rogers (1980) uses Quantum Theory as an example of a lack of causality. 
Quantum Theory is considered open and displays nonlinear movement similar to the open 
system proposed by Rogers (1970; 1980).  
 Patterns are used to identify the energy field. The pattern is perceived as a single 
wave, and embodies the characteristics of the energy field. This manifestation of a field 
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patterns occur due to the interconnection and mutual interaction between the 
human/environmental field. This idea coincides with Bohm’s (2006) theory of wholeness 
and implicate order, in which he describes the world as “Undivided Wholeness in 
Flowing Movement” (page 13). Pattern profile is a term used as a way to comprehend 
and explain the unitary qualities of individuals and their environment within SUHB 
(Rogers, 1980).  
Pandimensionality another concept of this framework is described as four 
dimensionality positing a world with no space or time, with no temporal attributes and is 
considered nonlinear in nature. In summary of the presented concepts, the unitary human 
being (human field) is considered an irreducible, four dimensional energy field. This field 
can be identified by pattern with specific characteristics that are different from the parts 
and cannot be determined or predicted from the parts. The human and environmental 
field are irreducible, infinite, integral and interconnected with one another. Rogers (1980, 
1986, 1992) proposed the pandimensional phenomenon of a nonlinear sphere, this may 
provide the fabric for the understanding of the paranormal realm. A view of reality where 
time and space are nonexistent and nonlinear allows for unexplainable events to unfold 
such as spiritual experiences.  
Principles of homeodynamics predicate the nature and direction of change, within 
the SUHB paradigm. Pattern is the key concept when observing these principles and 
proposes that change is continuous and nonlinear in nature (Barrett, 2000). As mentioned 
earlier Rogers’ (1970) uses Quantum Theory as an example of a lack of causality 
referring to the nature of change within an environment. Quantum Theory reveals the 
 
 38 
basic oneness of the universe characterized by patterns of energy waves, rather than solid 
matter or particles that are separated.  
The principles of homeodynamics that relate to the nature of change between 
person and environment include helicy, resonancy, and integrality. These concepts and 
the manifestation of field patterning have been used to study the experiences of 
individuals in nursing research over the years (Butcher, 1998; Kirton & Morris, 2013). 
Resonancy describes the continuous change from lower to a higher frequency wave 
pattern in human and environmental fields. Helicy is the continuous innovative and 
increasing diversity of human and environmental field patterns characterized by rippling, 
non repeating rhythmicities. Encompassed within this principle are the concepts of 
rhythm and evolutionary emergence of the unitary nature of man and environment in 
relationship (Rogers, 1980). The principle of integrality refers to the continuous mutual 
human field and environmental field process of mutual exchange of information.  
Metaparadigm Assumptions 
The unitary human being (human field) is considered an irreducible, four dimensional 
energy field. This field can be identified by pattern and specific characteristics that are 
different from the parts and cannot be determined or predicted from the parts. The human 
and environmental field are irreducible, infinite, integral and interconnected with one 
another. Humans are sentient thinking beings. Through awareness of self and 
environment there is an active aware participation in patterning. 
This paradigm assumes that individuals are aware and capable of making their 
own choices, and with increasing awareness they create change. Through this conscious 
decision making process they pattern their own field. In a study by Kirton & Morris 
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(2013) adherence to antiretroviral drugs in HIV participants was studied. The study was 
based on the construct of Power developed by Barrett (2000) using the SUHB paradigm. 
According to Barrett (1986; 2000), Power refers to a persons’ ability to participate 
knowingly in change by consciously making choices with awareness and intention. The 
purpose of Kirton & Morris’s study was to determine if there was a relationship between 
Power and treatment adherence in the HIV adult population.  
Although, the study findings did not indicate there was a relationship between 
Power and adherence, the evidence suggests the time frame of one day for data collection 
was not adequate. The authors acknowledge that future studies should be performed in a 
longitudinal format with repeated measures. Adherence is difficult to detect even over 
longer periods of time, however validity of this research may be enhanced by a longer 
time frame for measurement. Results may also suggest there is a gap in knowledge when 
individuals cannot knowingly participate in change. This may be related to a self-care 
deficit that occurs due to the reaction related to coping with a serious illness. Research 
indicates that the experience of a serious illness may cause alterations in a persons’ 
ability to engage in positive health behaviors (Andersen et al., 1994).  
There may be many factors associated with the inability to detect a relationship 
between Power and adherence. The inability to follow through with treatment may be 
associated with a decreased awareness of self and the environment. This may affect a 
persons’ readiness to perform self-care, due to emotional distress and feelings of being 
disconnected related to the illness. Other environmental influences such as treatment, 
medication regimen, lack of sleep, depression, anxiety or the experience of traumatic 
stress symptoms may affect adherence. The construct of Power is related to the person’s 
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ability to participate knowingly by consciously making decisions with awareness and 
intention (Barrett, 2000). Data suggests that treatment effects for any serious illness can 
be so destabilizing that a person may not complete their treatment (Andersen et al., 
1994).  
In the science of unitary human beings (SUHB), Rogers (1990) asserts that human 
energy fields are integral with environmental fields and are in a continuous interaction 
and exchange of energy. Numerous studies using the SUHB paradigm have shown how 
environmental influences can change an individual’s healing patterns. Another 
assumption of the SUHB is that humans are sentient, thinking beings. Through awareness 
of self and environment there is an active aware participation in patterning. If a person’s 
ability to be mentally or spiritually present is compromised due to trauma related to an 
illness or treatment of a serious illness, the person’s awareness may be compromised, this 
may affect the ability of the person to participate knowingly in change (Wu, Yang, 
Thayer, & Andersen, 2014). 
Considering this perspective the nurse can assist the patient in rebalancing and 
repatterning the energy field that surrounds them. According to Barrett (1988) nursing 
practice within the SUHB paradigm consists of two stages, pattern appraisal and 
purposeful mutual patterning to promote well being. This premise includes the nurse as a 
healing tool within the environmental field, therefore substantiates the need for nurses to 
have a conscious awareness of themselves when assisting others in the healing process. 
This may include the nurse consciously and intentionally caring for themselves in a 
healthful manner using exercise, yoga, music, meditation and spiritual practice to 
promote personal awareness. 
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The nurse consciously increases her/his vibrational frequency by balancing and 
promoting a healthy energy field for themselves and others. This in turn benefits the 
patient and environmental field as a whole. The use of light, sound and other alternative 
healing tools may be utilized to raise the vibrational frequency of the environment for the 
patient. (Barrett, 2000; Watson & Smith, 2002).  
According to Halldorsdottir (1991), patients can identify when a nurse is not 
present, detached, disinterested and uncaring, this feeling is interpreted by the patient as 
not healing. According to Rogers (1990), the human environmental field interaction is 
dynamic and infinite. Considering this perspective healing is contained within the greater 
field between patient, environment and nurse. The energy field holds the potential of 
healing according to the level of awareness and intention from the nurse, environment 
and patient. Within the SUHB paradigm health is referred to as a higher frequency of 
functioning. Activities that promote this change in pattern include; performing healthful 
behaviors in relation to the environment such as increasing lighting, the use of 
harmonious sound, maintaining and improving creativity, and patterning related to 
balance in the energy exchange with the environment.  
Knowledge Gap 
The emotional reactions related to the diagnosis and treatment of a serious illness 
can evoke feelings of panic, hopelessness, anger, depression, insomnia and memory 
problems (Andersen, Chatterjee, & Ershler, 2002; Hegel et al., 2006; Mundy & Baum, 
2004; Wu et al., 2014). Frequently healthcare providers do not recognize or adequately 
screen for these symptoms due to a primary unidimensional focus and lack of educational 
preparation. In a study of 598 patients diagnosed with glioma physicians reported 15% of 
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these patients had depression, whereas 93% of these individuals reported symptoms 
associated with depression that increased over a 6-month period of time (Lutofsky et al., 
2004). The quality of life and length of survival was considerably shorter for these 
patients. 
 The identification of predictors that affect the potential for breast cancer 
survivors to maintain adherence of adjuvant hormonal therapy is expected to increase 
knowledge of this problem, improve healthcare assessment, provide tools for educators, 
enhance quality of life for breast cancer survivors and introduce an integrated paradigm 
for research to improve evidence based practice. The use of the biobehavioral framework 
will examine the interrelationships between psychological responses, biological processes 
and health behavior outcomes. This knowledge can provide valuable insight that will 
improve intervention strategies to improve the quality of life for cancer survivors.  
Definitions 
Biobehavioral: refers to a focus on the interrelationships of stress, psychological, 
psychosocial, behavioral and the biological processes in disease and the treatment of 
disease. 
Adjuvant: defined as additional treatment following surgery, such as radiation, 
chemotherapy or hormonal therapy to prevent reoccurrence, adjuvant treatment may be 
systemic or local.  
Adjuvant Hormone Therapy: medication that is given to breast cancer survivors 
that slows or stops the growth of breast cancer by preventing estrogen-dependent cancer 
cells from obtaining estrogen. 
 
 43 
Correlational Design: investigates the degree that a relationship exists between 
two or more variables. 
Correlational Predictor Design: establishes a relationship between variables and 
uses the scores of one variable to predict the outcome of another variable.  
Adherence: defined for this study as the extent to which an individual follows 
medical instructions (Osterberg et al., 2005). Adherence will be a continuous variable 
with 85% or more of days, that medication is taken as instructed over the study.  
Traumatic Stress Reaction: defined as the response to a traumatic event that is 
sudden, shocking and uncontrollable, that may predispose an individual to PTSD 
symptoms (APA, 2013; Holland & Bultz, 2010). 
Depression: in cancer can be defined as a feeling of sadness most of the day that 
lasts longer than 2 weeks and is accompanied by tiredness, insomnia, worthlessness, lack 
of motivation, and poor concentration (NCI, 2009; APA, 2015). Although this may 
progress to the DSM IV definition of major depressive disorder (MDD), it may present 
different in individuals with a life threatening illness.  
Symptom Distress: is defined as the degree of discomfort from a specific  
symptom that is being experienced as self- reported by the patient. 
Unintentional Non Adherence: defined in this study as forgetting, memory lapse 
or ceasing treatment without making a conscious decision to stop. Defined in the 
literature as forgetting, memory problems, lack of understanding, difficulty processing 
information provided and the inability provide self- care (Andersen et al., 2008; Atkins & 
Fallowfield, 2006; Christenson, 1984 DiMatteo, 2007).  
 
 44 
Intentional Non Adherence: for this study will be defined as a conscious decision 
to stop the medication. Defined in the literature as a conscious decision not to take 
medication due to side effects, cost, inability to accept the diagnosis, and lack of 
resources including insurance or education (Atkins & Fallowfield, 2006; Barber et al., 






The literature search revealed a gap in knowledge base and understanding of the 
factors or predictors related to the problem of adherence with adjuvant hormonal therapy 
in breast cancer survivors. Although longitudinal evidence indicates adjuvant hormonal 
therapy can significantly improve survival rates for women diagnosed with breast cancer 
(Anderson et al., 2002; Barrios et al., 2009; Clemons & Goss, 2001; Hershman et al., 
2010), adherence to this medication is less than 50% (Hadji, 2010; Partridge et al., 2008; 
Ruddy et al., 2009). Despite more than five decades of research, there are major gaps in 
understanding the fundamentals of adherence particularly in breast cancer survivors.  
Previous studies attempting to determine predictors of adherence to adjuvant 
hormonal therapy in breast cancer have reported varying results and have attributed these 
differences to factors such as sample size, poor conceptual definitions, absence of 
standardized measures, and lack of an integrated theoretical research framework 
(Hershman et al., 2010; NCPIE, 2010; DiMatteo, 2003; DiMatteo & Haskard, 2006; 
Escalada & Grittiths, 2006).  
The purpose of this study was to examine the relationship between adherence and 
traumatic stress, depression, and symptom distress. The study also sought to determine 
whether or not non adherence is intentional or unintentional. A non-experimental 
correlational study using a prediction design was used to explore the influence of the 
independent or predictor variables of traumatic stress, depression, and physical symptoms 
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on the adherence to adjuvant hormonal therapy and whether this adherence is intentional 
or non-intentional. 
 This study used a biobehavioral framework to examine the problem of adherence 
to adjuvant hormonal therapy in breast cancer survivors. This theoretical framework was 
selected because previous research has emphasized the behavioral aspect of adherence, 
while the link between psychological and biological influences on health behavior 
outcomes has been unknown or overlooked (Bultz & Carlson, 2006; DiMatteo et al., 
2000; Matthews & Cook, 2008; Moreno-Smith et al., 2010; Shemish et al., 2004). This 
has limited the ability to fully research the problem of adherence to treatment in many 
illnesses, including breast cancer.  
Current research has indicated there is a bi-directional flow of interaction between 
psychological factors, neuroendocrine, and immunological responses at the biologic 
cellular, and molecular level and each has an effect on behavioral change, (Miller & 
Raison, 2008; Starkweather et al., 2011) modulate neurocognitive change, and 
psychological responses (Dantzer & Kelley, 2007; Raghavendra et al., 2004). Although 
this study did not directly measure the biological markers associated with traumatic 
stress, symptom distress, and depression the study did examine the relationship between 
adherence and intentionality within a biobehavioral framework. 
The following research questions were used to guide the design and analysis for 
this study:  




 RQ2: What is the impact on intentional/unintentional non adherence of 
traumatic stress, depression, and symptom distress? 
Research Method 
This study used a quantitative method to explore relationships between adherence 
to treatment and intentionality. The term intentionality was used to describe the 
participants’ desire to maintain adherence to adjuvant hormonal therapy during the study. 
This term was derived from the definition of unintentional non adherence, that is related 
to the experience of a memory lapse, forgetting, unconsciously stopping treatment and 
difficulty processing or understanding the reasons for taking the medication (Atkins & 
Fallowfield, 2006; Barber et al., 2004; Lehane & McCarthy, 2007). Whereas, intentional 
non adherence is related to a patient making a conscious decision not to take a medication 
due to side effects, cost, lack of insurance, or education (Atkins & Fallowfield, 2006).  
Quantitative research methods were selected over qualitative and mixed methods 
studies. A qualitative study might have led to insight into the behavior and thinking of a 
small number of breast cancer patients; however, this was not the intention of this study. 
This study sought to identify factors affecting adherence to treatment not understand why 
or how women choose to do this. A mixed method study combines qualities of 
quantitative and qualitative data in one study allowing the exploration of a topic in some 
detail with qualitative data and also exploring the topic with quantitative data. While 
mixed methods studies can add to the literature, they go beyond the scope of this study. 
The purpose of this study was to explore factors affecting adherence to a breast cancer 
regime and intentionality in adherence and a quantitative methodology was selected as 
the most appropriate for this study in predicting adherence. The intention of this study 
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was to be objective and unbiased as possible, allowing the numbers and responses of the 
breast cancer patients to be analyzed to determine whether or not predictors of adherence 
and intentionality could be identified. A quantitative method was selected as most 
appropriate for this study.  
Research Design 
This study used a non-experimental correlational design to identify a statistically 
significant predictor or combination of predictors contributing to the adherence with 
adjuvant hormonal therapy and intentionality. Correlational research is used to examine 
the relationships between two or more unmanipulated variables. In a correlational design 
using regression analysis, a set of predictor or independent variables are used to predict 
the dependent or predicted variable. There is no manipulation in a regression 
correlational study as there is no control or comparison group (Portney & Watkins, 
2009).  
The predictor variables, traumatic stress, depression, and symptom distress, were 
used to determine their contribution to the dependent variable of adherence to adjuvant 
hormonal therapy and intentionality. A correlational design using a regression/prediction 
design was selected because prior research has documented the connection between 
depression, traumatic Stress and side effects with a lack of adherence (Burgess et al., 
2005; DiMatteo, 2003; Holland & Bultz, 2010; NCI, 2009), and the relationship between 
the effects of traumatic stress and adherence in breast cancer survivors has not been 
empirically examined. Additionally, none of these predictors have been selected as the 
most appropriate for this study in predicting adherence..  
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A correlational design using a predictor method is consistent with the purpose of 
this research for the following reasons: (a) the variables were not manipulated 
experimentally (b) there was a single group population as opposed to including a 
randomly assigned group (c) the independent outcome variable occurred naturally 
without any intervention. Correlational designs are appropriate for the development of 
theories and theoretical models for future research (Oman, Krugman & Fink, 2003). The 
predictor variables were measured one time at the beginning of the study using the BCS. 
Following the BCS the adherence variable was measured using MEMS bottles and two 
prearranged phone calls for the remainder of the study.  
A correlational regression design was used to develop a model for predicting 
adherence or intentionality with traumatic stress, depression, and physical symptoms/side 
effects as the predictor or independent variables. Correlational designs cannot predict a 
causal relationship, however, it can provide evidence a relationship exists between the 
predictor(s) and the outcome criterion variable.  
Study Participants 
Participants in this study were recruited from five breast cancer clinics in the 
Rocky Mountain region including four clinics of Rocky Mountain Cancer Centers 
(RMCC), University and University Hospital Anschutz Breast Cancer Center 
(UHABCC), breast cancer support groups, and breast cancer survivor events in the Rocky 
Mountain Region. All four RMCC outpatient breast cancer treatment centers have 
between 200–300 new cases of breast cancer cases every year and UHABCC has 
between 300-350 per year. 
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The study used a convenience sample of volunteers meeting study criteria. A 
convenience sample is a non-probability type of sample and while not appropriate for 
experimental studies, is acceptable for a correlational study design (Portney & Watkins, 
2009). Recruiting from multiple treatment sites may have improved the generalizability 
and every effort was be made to include diversity within the sample.  
The convenience sample included women diagnosed and treated for breast cancer 
stages I-IV after completion of all other treatment and within 24 months of beginning 
adjuvant hormonal therapy. All participants completed a single or multimodal adjuvant or 
neo-adjuvant treatment plan. Adjuvant or neo-adjuvant treatment may include surgery, 
radiation, chemotherapy, biological modifiers (e.g. Trastuzumab, bevacizumab, etc.), 
targeted therapies (e.g., lapatnib etc), and agents given in a clinical trial for early stage 
breast cancer. Adjuvant hormonal therapy was initiated within 24 months following all 
other treatment and/or surgery. This was the participant’s first diagnosis of any cancer 
and participants were fluent in English speaking and writing. Only after completing all 
other treatments did participants begin adjuvant hormonal therapy. Participants were 
between 18-70 years of age. The age of 70 was selected as the cutoff for the following 
reasons: recovery time, co-morbid illness, and possible memory problems related to ages 
greater than 70 years. 
Informed Consent 
Creswell (2014) suggested the fundamental role for ethical research is to do no 
harm, including physical, psychological, social, economic, or legal. Every research 
participant in a study has a right to privacy and the expectation the data is kept 
confidential at all times. Potential participants in this study were informed of the intent of 
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the study, the voluntary nature of the study, the rights of study participants, contact 
information if the participant had questions, and procedures to be used. The participants 
received the Informed Consent Form (Appendix C). Breast Cancer patients agreeing to 
engage in the study signed and returned the Informed Consent form to the investigator 
during the initial meeting. The collection of the Informed Consent form included subjects 
between the ages of 18 and 70 years meeting the eligibility criteria previously stated for 
participation in the study. 
Confidentiality  
The right to privacy and confidentiality disclosure to participants prior to the start 
of a research project is important because this allows participants to decide whether to 
participate (Creswell, 2014). Every research participant has the right to expect there will 
be no chance of identification by name at any time, before, during, or after a study. The 
identity of subjects will remain confidential and anonymous. Participants in the study are 
voluntary and no one else will have access to the data. An Informed Consent form 
explained privacy and ethical issues to subjects as well as voluntary participation.  
The data collection process did not include personally identifying information as a 
part of the study and the data report is in aggregated format. The identity of the 
participants will remain confidential and anonymous by using a numeric code for all 
participants. Each informed consent and all data were labeled with each individual’s 
unique identification number. Paper copies of informed consent forms and HIPAA 
release forms will be kept separate from data and stored in a separate locked file. A 
password-protected Excel spreadsheet containing participants’ personal information will 
be stored on a CD separate from the data files in a locked file cabinet at the researcher’s 
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home office. The data gathered will be used only for the purposes of the current research 
and the CD and hardcopy documents will be destroyed three years after the end of the 
study by the researcher in a cross cut shredder and by magnetizing and shredding the CD. 
Data Collection 
Data collection did not commence until permission to conduct the study was 
received from the Colorado Multiple Institutional Review Board (COMIRB) of the 
University of Colorado. The data collection occurred in a series of steps as follows: 
advertisement and recruiting of participants (Appendix A), screening of participants 
(Appendix B), collection of informed consent form (Appendix C), HIPPA release forms 
(Appendix D), collection of the study questionnaire (Appendix F), and adherence data 
over the course of the study period using the medication event monitoring system 
(MEMS) bottle, self- report and pill count form (Appendix I). Several methods of data 
collection occurred during the study including in person, telephone and electronic 
monitoring.  
Advertisement and Recruiting 
Participants for this study were recruited through a variety of methods including 
advertisements, websites, and patient packets. All advertising and recruitment materials 
contained the researcher’s contact information by telephone and Internet. Advertising 
materials contained basic information about the study, and inclusion criteria. Advertising 
flyers (Appendix A) were posted in IRB approved sites. The advertising materials were 
also posted at the researcher’s study website address at www. breastcancerinfo.com. 
Adverstisement flyers were available at four Rocky Mountain Cancer Centers (RMCC) in 
the Metro Denver area and University of Colorado Hospital Breast Cancer Clinic.  
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Potential participants interested in the study were asked in the advertising to 
contact the researcher by telephone or email. When participants contacted the researcher 
by telephone or email, the researcher carefully screened potential participant to be certain 
they met the inclusion/exclusion criteria for the study (Appendix B). The study was 
explained along with a time line and the process for collection of data. The participant 
was asked if they would like to participate in the study and meet for an initial visit. In this 
meeting the participants received more information, signed the Informed Consent, 
HIPAA release, provided instructions for the MEMS cap and filled out the Breast Cancer 
Survey (BCS). Each subject was informed about the two phone calls they would receive 
during the study period. Participant names and contact information is kept in a locked file 
in the researcher’s home office separate from the data and separate from all consent and 
release forms. Each study participant was assigned a numerical identification number and 
the list with number and name will be kept in a locked file in the researcher’s home 
office. Only the identification number was recorded on all other materials for the study 
and all names were removed.  
Measures 
The Breast Cancer Survey (BCS) (Appendix F) was provided to participants 
during the initial meeting between researcher and participant. Instructions were provided 
and any questions answered prior to subjects completing the BCS. The survey was 
collected by the researcher after being filled out by the participant. The BCS (Appendix 
F) contains demographic information, the CES-D and IES, (Weiss, 2007; Horowitz, 
Wilner, & Alvarez, 1979) and the adapted Psychological Symptom Distress Scale. The 
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BCS was administered only once to all study participants. After participants completed 
the BCS, the data was downloaded and prepared for statistical analysis.  
Adherence Data 
Adherence was measured using several different methods. The Medication Event 
Monitoring System (MEMS) caps was the primary adherence measurement in this study. 
MEMS are medication bottles that contain a microchip in the lid. The microchip 
electronically records the date and time the pill bottle is opened (Christensen, 2014; 
Cook, Schmiege, McClean, Aagaard, & Kahook, 2011; Reikert, 2006). Adherence using 
this method was calculated as the percentage of doses taken over the study period, with 
85% of the total doses taken considered adherent. The MEMS data was computed over 
multiple time points consisting of every 30-day increments.  
Adherence data collection also involved making two phone calls to participants at 
randomly selected times during the course of the study. The phone calls were 
unannounced to participants and dates were randomly selected. Information about the 
study indicates participants were told they would be called twice during the course of the 
study but no exact time was provided in the description of the study. During each of the 
phone calls, participants were asked to get their prescription bottle(s) and the MEMS 
bottle. The Pill Contact Form (PCF) was used for the phone calls (Appendix I) and 
provided the following questions that were answered: prescription name, date 
prescription was filled, total number of pills prescribed, number of pills to be taken every 
day, and number of pills remaining in the bottle. Two questions on the PCF were also 
included; 1) How often do you forget to take your medication? 2) How often do you 




The descriptive data collected for this study included age, ethnic identification 
group, completed educational level and the participant’s stage of breast cancer. 
Participants were asked to provide their current age as a continuous variable and to 
choose between the following ethnic groups: Caucasian, African American, Hispanic, 
Asian/Pacific Islander, American Indian, Mixed, and other with a blank to write in their 
choice of group. Completed educational level consists of seven levels ranging from less 
than high school to Doctorate/Professional degree. Study participants were asked to 
indicate the stage of their breast cancer ranging from pre-cancerous (Stage 0) to Stage 4. 
The descriptive data collected for this study was used to provide a description of the 
participants. 
Instruments 
This study collected data on a number of different variables. Each variable, 
questionnaire, or assessment is described in the sections below. No data was collected 
until all HIPPA and informed consent forms were signed. Variables for the study include 
the following: depression, traumatic stress, symptom distress, adherence, intentionality, 
and demographic data. 
Self-report measurements have a moderate to high correlation of adherence with 
Medication Electronic Measurement Systems (MEMS) (Haynes et al., 1980). Although, 
self-report is an indirect and easy measurement it can effectively measure adherence 
(Atkins & Fallowfield, 2006; Tan, Patel, Chang, 2014; Walsh, Mandalia, Gazzard, 2002). 
In a large literature review of 1,026 studies on self-report measures, Garfield, Clifford, 
Eliasson, Barber and Willson (2011) reported that a small number of these studies 
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presented internal test-retest reliability. Of those studies that presented this data the 
reliability was acceptable with Cronbach’s alpha 0.6–0.9, ICC & Kappa 0.7. The findings 
in this literature search indicated that patients can estimate general adherence when a few 
questions are presented; rather than a longer and more complicated self-report 
measurement. The most effective test of validity for self -report instrument is by checking 
the measure against other adherence measures.  
Center for Disease for Epidemiological Studies–Depression Scale (CES-D) 
Depression was assessed using the Center for Epidemiological Studies-
Depression Scale (CES-D) (Radloff, 1977). The CES-D (Appendix G) is a 20-item scale 
designed to measure depression and has been used successfully with different populations 
for more than 35 years. Cronbach alpha reliability coefficients range from α=0.86 to 0.94 
indicating a high level of internal consistency and reliability. Test/retest reliability 
appears stable even for up to 1 year (r=0.40 to r=0.70). Four of the items need to be 
reverse scored (Eaton, Muntaner, Smith, Tien, & Ybarra, 2004). Radloff (1977) reported 
Cronbach alpha coefficients ranging from 0.85 to 0.90 and higher scores on the CES-D 
indicate having more depressive symptoms.  
The CES-D contains four constructs/subscales including: depressed affect, 
positive affect, somatic activity, and interpersonal. The CES-D utilizes a four point Likert 
type response scale of Rarely (0) Some of the Time (1) Occasionally (2), and Most of the 
Time (3). Eaton et al. (2004) noted the CES-D takes approximately 10 minutes to 
complete and has been translated into several languages. Construct validity has been 
established using the Beck Depression Inventory (Beck, Ward, Mendelsen, Mock, & 
Erbaugh, 1961) and the Zung Depression Scale (Zung 1965). The CES-D is available in 
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the public domain and used in many academic and research settings (Bakitas et al., 2009; 
Kreutz, Frierson, Andersen, 2002; McCorkle, Siefert, Dowd, Robinson, & Pickett, 2007). 
Impact of Events Scale  
The Impact of Events Scale (IES) (Appendix H) has been widely accepted as a 
measure of traumatic stress experienced after a traumatic event or life stressor (Corcoran 
& Fisher, 1994; Sundin & Horowitz, 2002). Horowitz et al., (1979) validated the IES to 
identify post traumatic stress disorder (PTSD) symptoms. The IES consists of 15 items 
and is a standardized self-report examining cognition involving re-experiencing. The IES 
consists of two main subscales including Intrusion (7 items) and Avoidance (8 items). 
The IES will be adapted for cancer patients by slight rewording of the items by replacing 
the word ‘it’ with cancer.  
The IES is a widely applicable self-report measure designed to assess current 
subjective distress for any specific life event (Corcoran & Fischer, 1994; Horowitz et al., 
1979). It is an instrument that can be used for repeated measurement over a period of 
time. Its sensitivity to change provides the ability for monitoring the client’s progress in 
therapy (Corcoran & Fischer, 1994).  
The original IES had 20 items (Horowitz et al., 1979) and was revised to a 15 
item self-report scale measuring symptoms of posttraumatic stress disorder (PTSD). The 
reduction in items contains 15 of the most significant symptoms reported in PTSD that 
are intrusion and avoidance. These items are highly correlated with the DSM-V listed 
symptoms for the diagnosis of PTSD. The Intrusion subscale has 7 items rating intrusive 
thoughts, intrusive feelings, nightmares, and imagery associated with the traumatic event. 
The Avoidance subscale has 8 items rating avoidance of emotions, ideas, and situations 
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The split half reliability on the total scale was high with r = 0.86. Internal 
consistency of subscales with Cronbach’s Alpha was Intrusion: 0.78 and Avoidance: 
0.82. Test-retest reliability was 0.87 for total stress scores, 0.89 for intrusion scores and 
0.79 for avoidance subscale scores. The reliability of the IES is very good. Corcoran and 
Fischer (1994) reported the subscales of the IES indicated very high internal consistency 
based on numerous sample groups. The coefficients ranged from 0.79 to 0.92, with an 
average of 0.86 for the intrusive subscale and .90 for the avoidance subscale 
 Participants were asked to indicate how cancer may have created or is causing 
stress in their lives. Individuals were asked how disturbing an event was and assesses the 
intensity of intrusive thoughts, hyper-arousal, and avoidant behaviors within this time 
frame. Responses are based on a 4 point Likert type response scale; Not at All (0), Rarely 
(1), Sometimes (2), Often (3).  
Limitations of the IES include: higher scores in specific populations such as 
African Americans, and the instrument cannot be used as a comprehensive diagnostic 
tool for PTSD. The IES is used specifically to measure a specific event and this needs to 
be explained to the participant taking the test. Strengths of the IES include; the tool is 
short, is easy to administer, has been reliable in repeated measures to assess progress, and 
has a high correlation with the DSM-IV and DSM-V diagnosis of PTSD.  
The CES–D and IES are scales that have been used consistently for many years in 
many different studies including breast cancer. They are both scales that are considered 
reliable and valid instruments. 
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Psychological Symptom Distress Scale (PDS) 
Frequently women with breast cancer experience problems with psychological 
symptom distress from treatment or the disease process. Numerous studies indicate that 
20% - 40% of individuals experience psychological symptom distress during the cancer 
experience (Holland & Allici, 2010). The term distress was chosen by the National 
Comprehensive Cancer Network (Holland & Bultz, 2010) to avoid the negative stigmas 
associated with the words psychiatric, emotional, or psychological. The primary focus of 
biomedical care is the treatment of physical health problems associated with cancer, 
while emotional, environmental, spiritual or psychological issues are frequently 
unrecognized or neglected (Lutofsky et al., 2004). For this reason measuring 
psychological symptom distress during the cancer trajectory was a focus for this study.  
A review of several symptom distress scales was performed to find a scale that 
adequately measures psychological symptom distress in cancer. The review of scales 
included the Brief Symptom Inventory 18 (BSI 18), Kessler Psychological Distress Scale 
(K-10), Symptom Distress Scale (SDS) (McCorkle & Young, 1978), and the Symptom 
Checklist 10 (SCL-10). (Derogatis, Melisaratos, 1983; Haes, Knippenberg, & Neijt, 
1990; Kessler, 2000; McCorkle & Young, 1978; Rosen et al., 2000). The BSI, K-10, and 
the SCL-10 are well validated instruments that measure psychological distress. The SDS 
developed by McCorkle and Young (1978) measures physical symptoms during the 
experience of cancer. After completing this review it was determined that a scale that 
would measure psychological symptom distress was most appropriate for this study. 




The PDS items were developed using a literature review with comparison and 
review of numerous symptom distress scales. The PDS is a 15 item scale with responses 
based on a 5 point Likert scale; Not at All (0), A Little Bit (1), Moderately (2), Quite a 
Bit (3), Extremely (4). Participants were asked to rate how much they were distressed by 
each item over the last 7 days. The PDS scale was tested for reliability and validity in this 
study. The reliability of the PDS was high with a Cronbach’s alpha of (0.833), however 
there was a validity problem with high overlap with the CES-D and the IES instruments.  
Adherence 
Adherence was the dependent variable and was assessed using the MEMS caps, 
the Pill Count Form (PCF) and Medication Possession Ratio. The purpose of the PCF 
was to collect the patients’ intentionality data. Adherence is defined as, “the extent to 
which an individual follows medical instructions” (Osterberg & Blaschke, 2005, pp. 487-
497; Ruddy, 2009; NCI, 2009). Despite numerous methods for measuring adherence, 
there are no methods without significant limitations and there is no universally accepted 
method. Adherence measurements in cancer therapy have been based primarily on self-
report measures (Partridge et al., 2002). Studies indicate self-reported adherence rates 
may be higher if patients know they are being monitored (DiMatteo & Haskard, 2006; 
Partridge et al., 2008; Ziller, 2009). Direct questioning of patients to evaluate adherence 
may improve the reliability of self-report. At the present time there is minimal empirical 
research using a standardized definition for adherence validating the reliability of self-
report measures in cancer populations (Escalada & Griffiths, 2006; NCI, 2009). The use 
of several methods including Medication Event Monitoring Systems (MEMS), self-
 
 61 
report, pill counts and medication possession ratio (MPR) method may improve this gap 
in knowledge for breast cancer survivors (Hadji, 2010). 
Medication Event Monitoring System 
The primary adherence measure for this study was the Medication Event 
Monitoring System (MEMS) caps. MEMS are medication bottles that contain a 
microchip in the lid. The microchip electronically records the date and time the pill bottle 
is opened (Cook, et al., 2011; Diaz et al., 2001). Adherence using this method was 
calculated as the percentage of doses taken over the study period, with 85% of the total 
doses taken considered adherent. The MEMS data were measured at multiple time points, 
these measurements occurred every time the bottle was opened. 
Pill Count Form 
The pill count form was a self-report measure completed by the researcher during 
each phone call. The purpose of the Pill Count Form was to measure the number of pills 
prescribed, number of pills taken per day, and the number of pills remaining in the bottle. 
It also included two questions that addressed the intentional and unintentional non 
adherence (Appendix I). 
Medication Possession Ratio 
Self-report method with a phone interview or e-mail has been validated with other 
measures in numerous studies including cancer, using a multimethod approach (NCIE, 
2010; Steel, Nwokik, & Joshi, 2007; Baker & Brandon, 1990). Although the reliability of 
self report has been questioned, it is important to consider the patients’ perspective of 
adherence. The two unannounced phone calls were used in an attempt to validate the 
MEMS measure of adherence.  
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Assessment of adherence was attempted to be measured using a self-report and 
pill count process similar to the one used by Steel et al., (2007). Steel and colleagues 
calculated adherence as a percentage using the following formula: 
Dispensed pills–pill remaining 
_________________________ * 100 = Adherence percentage 
Expected to be taken 
This study attempted to use this formula for calculating the adherence percentage. 
All information was obtained through a phone call with the participants from information 
available on the medication container/bottle. The researcher completed the pill count 
form during two unannounced phone calls to participants over the study time. A 
percentage of adherence was calculated for each of the two monitoring calls during the 
course of the study using the pill count form.  
Intentionality 
Two items on the Pill Count Form were used to measure intentional or 
unintentional non adherence; the term used to describe these variables is intentionality. 
Unintentional non adherence was defined as forgetting, memory lapse, or ceasing 
treatment without making a conscious decision to stop (Andersen et al., 2008; Atkins & 
Fallowfield, 2006; DiMatteo, 2007). Intentional non adherence was defined as a 
conscious decision not to take medication due to side effects, cost, inability to accept the 
diagnosis, and lack of resources including insurance or education (Atkins & Fallowfield, 
2006; Lehan & McCarthy, 2007; Barber et al., 2004). Participants were asked two 
questions: How often do you forget to take your medication and how often do you choose 
not to take your medication? The response format for these two items consisted of a 
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Likert type scale: Never (0), Occasionally (1), Sometimes (2), Quite Often (3), Very Often 
(4). This was an investigator created tool and the psychometrics were tested in this study. 
These items were developed using a literature review with comparison of many self-
report scales measuring general adherence, intentional non adherence and unintentional 
non adherence. The literature indicated that numerous studies have shown that measures 
with less questions have a higher correlation with adherence (Garfield et al., 2011).  
Validity and Reliability 
In descriptive predictive research there is no treatment group and no control or 
comparison group; however, it is still important to consider the validity and reliability of 
the study. Study validity can be thought of as internal or external. External validity refers 
to the generalizability of the study results or would the same result be found with another 
group of participants, in another setting, or at another time. To what other populations, 
settings, or measurement variables could the findings of the study be generalized? Ary, 
Jacobs & Sorenson (2010) identified three types of external validity: population, 
ecological, and external validity of operations. Population external validity concerns 
identifying other populations to which the findings of a study might be generalizable. 
Population validity addresses how the subjects were selected for a study. The study used 
a convenience sample of volunteers opting to participate in the study and generalizing to 
other populations in different situations or with different diseases would be difficult. 
There is no threat from interaction between subjects and treatment; however, using 
volunteers does present a problem. Volunteers may have characteristics atypical of the 
population and no one knows how or why non-volunteers would have answered the items 
on the surveys or why they did not volunteer (Ary, Jacobs, & Sorenson, 2010). 
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Ecological validity is concerned with generalizing of the study results to other situations. 
Before generalizing the study results, care needs to be taken to consider the environment 
in which the research was done; threats to ecological validity (pre-testing, novelty effect 
of a new treatment, or attitudes developed over the course of the study) do not present 
problems in the study. However, knowledge that you will be called to check on adherence 
may affect how the volunteers desire to take their medication.  
External validity of operations addresses how the study was conducted with 
specific operational definitions. Would the same results be expected with different 
investigators using different operational definitions or measurement procedures? The 
constructs proposed by the study for investigation are derived from the instrument 
developed for the study.  
Campbell and Stanley (1963) also discussed internal validity and distinguished 
between research designs in terms of internal validity. The authors defined internal 
validity as the extent to which extraneous variables are controlled by the researcher. 
Extraneous variables are those variables that may affect the outcomes of a study. The 
eight factors related to internal validity (history, maturation, testing, instrumentation, 
statistical regression, differential selection, experimental mortality, and selection 
maturation interaction) may be a concern in this study. History might present a problem, 
as there might be some occurrence in the participant’s life or in the world at large that 
might affect how study participants would answer the items on the surveys to be included 
in the study. The occurrence of outside events (personal, organizational or world) is 
beyond the control of the researcher; however, any occurrence will be noted in the study 
if necessary. Maturation may not have been a problem due to the short time line for the 
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study and the participants being adults whose developmental sequence is not as rapid as 
in young children. Testing may not be a problem as there is no pre-testing involved in the 
study. Instrumentation is established as the instruments to be used in the study have been 
demonstrated to be valid and reliable, measure the constructs desired for the study, and 
are appropriate for the participants in the study. Since there was no repeated measures, 
statistical regression to the mean does not present a problem; however differential 
selection may be problematic as the study used a convenience sample of women being 
treated for breast cancer. Selection maturation interaction is also not a problem as the 
study’s participants are all adults and not liable to change over the short time of the study. 
Experimental mortality or subjects dropping out of a study was not a serious problem. 
Possibilities exist a participant might start a survey but not complete it or the response 
rate might be very low, although this did not occur in this study. Measurement validity 
and reliability were addressed in the instruments section of the study. 
Researchers have the responsibility to their respective professions to ensure the 
highest levels of validity and reliability of instruments used in a study (Neuman, 2006). 
Internal validity is the measurement of how well the research instrument matches the 
specific targeted constructs (Cooper & Schindler, 2008). Maintaining the highest degree 
of internal validity and its various concepts is a goal of the proposed study.  
The predictive validity of the study was decided after the data had been collected 
and analyzed. External validity refers to the genearalizabilty of the study results or would 
the same result be found with another group of participants, in another setting, or at 
another time. Cronbach’s coefficient alpha was used to ensure reliability among items on 




The analysis of the data collected for this study occurred in a set of sequential 
steps. The first step was to complete descriptive statistics including mean, median, mode, 
standard deviation and frequencies for all variables. This first step served the purpose of 
checking the data for data entry errors and reviewing the data. The second step in the data 
analysis was to calculate reliability for the scales and subscales used in the study. A 
Cronbach alpha was used to calculate reliability and internal consistency for the scales 
and subscales. A probability level of p=.05 was used to determine statistical significance 
for the procedures used in testing the hypotheses. 
For any questions in the survey that were left unanswered, the typical answer 
from the participants total scale was used for this missing data. All missing data in the 
analysis was treated as missing data and no effort was made to impute scores for missing 
data within the MEMS data. 
The first null and alternative hypothesis to be addressed in the study is as follows: 
HO1: There will be no statistically significant predictors of adherence using 
traumatic stress, depression, and symptom distress. 
HO1a: There will be statistically significant predictors of adherence using 
traumatic stress, depression, and symptom distress. 
Prior to commencing the analysis, the data was assessed to ensure the 
assumptions of regression have were met. The assumptions of multiple regression are as 
follows: 1) the independent variables (IV) are fixed and the same values on the IVs 
would be would be used if the study were to be replicated; 2) the IVs are measured 
without error; 3) the relationship between the IVs and dependent variable (DV) is linear; 
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4) the mean of the residuals for each observation on the DV over replications is zero; 5) 
errors associated with any single observation on the DV are independent or not correlated 
with errors associated with any other observation on the DV; 6) the errors are not 
correlated with the IV; 7) the variance of the residuals across all values of the IV is 
consistent or homoescedasticity of the variance of the residuals; and 8) the errors are 
normally distributed. Assumptions 1, 2, and 4 are research design issues. Assumptions 3, 
5, and 6 address linearity and assumptions 7 and 8 address homoscedasticity and 
normality.  
Normality was evaluated using skewness, kurtosis, and Kolmogorov-Smirnov 
statistics and linearity was assessed through inspection of bivariate scatterplots. 
Homescedasticity was assessed through interpreting the results of Box’s M Test. 
Alternatively; a typical procedure is to examine residual scatterplots. Examination of the 
residual scatterplots provides a test of each of these three assumptions (Tabachnick & 
Fidell, 1996). The assumptions of linearity, normality, and homoscedasticity were 
tenable, and the points of the scatterplot clustered along the horizontal line in a somewhat 
rectangular pattern. Any systematic, differential patterns or clusters are an indication of 
possible model violations (Tabachnick & Fidell; Stevens, 1996).  
An additional problem with multiple regressions is the existence of multi-
collinearity. Multi-collinearity is a problem arising when there are moderate to high 
intercorrelations between predictor variables. The problem happens when two or more 
variables are measuring essentially the same information (Sprinthall, 2006). Little is 
gained by adding variables to a regression analysis measuring the same thing and multi-
collinearity can cause real problems with the analysis. Stevens (2009) pointed out three 
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reasons why multi-collinearity can cause problems. They include: (a) multi-collinearity 
limits the size of the R since the IVs are going after much the same variability in the DV, 
(b) multi-collinearity can cause difficulty because effects are confounded when there is 
overlapping information, and (c) multi-collinearity tends to increase the variances of the 
regression coefficients resulting in unstable prediction equations. The simplest method of 
diagnosing multi-collinearity is to check for high inter-correlations between the predictor 
variables. A second method is to inspect the variance inflation factor (VIF), an indicator 
of the relationship between predictors (Stevens, 2009). Stevens also noted VIF values 
greater than 10 are generally cause for concern. The data for all regression analyses was 
assessed so multi-collinearity did not present a problem in the analysis. There was high 
multicollinearity between the CES-D and PDS scale; due to this problem the PDS was 
taken out of the final analysis. 
When the data were assessed to ensure the assumptions were met, a sequential or 
hierarchical regression was attempted. In a hierarchical or sequential, blocks are used to 
enter specific variables, predictors or covariates, into the model in groups. Entering the 
data in groups allows isolation of the effects of these specific variables in terms of the 
predictive model and the relative contribution of variables in each block. Sequential or 
hierarchical regression was used to assess the contribution of descriptive variables to the 
model. A stepwise multiple regression was also used to assess the contribution or 
variance accounted for by each of the predictor variables, the subscales and 
unidimensional scale scores. Stepwise multiple regression is often referred to as a 
statistical multiple regression. When there are multiple predictor variables, a statistical 
multiple regression may be used to determine the IVs contributing to the model (Mertler 
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& Vannatta, 2001). Forward, stepwise, and backward are methods of entering and 
keeping variables in the model. At each step in a stepwise regression, tests are performed 
to determine the significance of each IV already in the equation. If a variable entered into 
the analysis was measuring the same construct as another, a reassessment of the variables 
might conclude the first variable is no longer contributing anything to the analysis. In a 
stepwise selection procedure, the variable would then be dropped out of the analysis even 
though it might have been a good predictor at one time. The variable may not be found to 
provide a substantial contribution to the model (Mertler & Vannatta, 2001). The second 
null and alternative hypothesis posed for the study is as follows: 
HO2: There will be no statistically significant predictors of 
intentional/unintentional adherence using traumatic stress, depression, 
and symptom distress. 
HO2a: There will be statistically significant predictors of 
intentional/unintentional adherence using traumatic stress, depression, 
and symptom distress. 
The second hypothesis asks if traumatic stress, depression, and symptom distress 
scales or subscales are predictors of intentionality to adhere or not adhere to a treatment 
regime. The DV intentionality, is a continuous variable and was measured using Multiple 
Regression analysis. This is a method used when there is more than one independent 
variable (IV). The assumptions of multiple regression are listed previously and they are 
as follows: 1) the independent variables (IV) are fixed and the same values on the IVs 
would be would be used if the study were to be replicated; 2) the IVs are measured 
without error; 3) the relationship between the IVs and dependent variable (DV) is linear; 
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4) the mean of the residuals for each observation on the DV over replications is zero; 5) 
errors associated with any single observation on the DV are independent or not correlated 
with errors associated with any other observation on the DV; 6) the errors are not 
correlated with the IV; 7) the variance of the residuals across all values of the IV is 
consistent or homoescedasticity of the variance of the residuals; and 8) the errors are 
normally distributed. Assumptions 1, 2, and 4 are research design issues. Assumptions 3, 
5, and 6 address linearity and assumptions 7 and 8 address homoscedasticity and 
normality. 
As previously stated normality was evaluated using skewness, kurtosis, and 
Kolmogorov-Smirnov statistics and linearity was assessed through inspection of bivariate 
scatterplots. Homescedasticity was assessed through interpreting the results of Box’s M 
Test. An additional problem with multiple regressions that was listed previously is the 
existence of multi-collinearity. This may occur when there are moderate to high 
intercorrelations between predictor variables. The data for all multiple regression 
analyses was assessed so multi-collinearity was not a problem in the analysis. If multi-
collinearity does exist, a variable would be deleted or variables may be combined to 
create a single construct.  
Multiple regression is an appropriate choice for developing a model to predict 
whether or not an individual adheres or does not adhere to a drug regimen. . To address 
correlation issues, a multicollinearity diagnostics on the multiple regression analysis was 
conducted. The diagnosis identifies all correlation issues, inspects the variance inflation 
factor, and reviews tolerance to identify what variables might be problematic. 
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Problematic variables will be deleted or combined. The significance of each regression 
coefficients will be assessed via a Wald Test for each variable..  
Summary 
The purpose of this study was to examine the relationship between adherence and 
traumatic stress, depression, and symptom distress. The study also sought to determine 
whether or not non adherence is intentional or unintentional. To my knowledge this is the 
first study that has explored adherence to adjuvant hormonal therapy in breast cancer 
survivors using a biobehavioral framework. This research will contribute to the gap in 
knowledge and understanding of the factors and predictors related to the problem of 
adherence to adjuvant hormonal therapy. Goals of this research include: 1) The 
improvement of healthcare for breast cancer survivors and those that suffer from long 
term serious health conditions; 2) Develop education strategies and programs for 
healthcare professionals to improve healthcare outcomes; 3) Increase awareness of the 
biobehavioral perspective to promote an integrative approach whole health perspective 
for breast cancer survivors. Overall, identifying predictors related to adherence within a 
biobehavioral framework will benefit adherence research, by promoting effective 







The purpose of this study was to examine the relationship between adherence and 
traumatic stress, depression, and symptom distress. The study also sought to determine 
whether or not non adherence is intentional or unintentional. A non-experimental 
correlational study using a prediction design was used to explore the influence of the 
independent or predictor variables of traumatic stress, depression and symptom distress 
on the adherence to adjuvant hormonal therapy and whether this adherence is intentional 
or unintentional. This study used a biobehavioral framework to examine the problem of 
adherence to adjuvant hormonal therapy in breast cancer survivors. The biobehavioral 
model of cancer stress (BMCS) offers a multidimensional approach to research the 
problem of adherence to adjuvant hormonal therapy in breast cancer survivors. This 
framework offers a comprehensive explanation of the mechanisms for psychological, 
environmental and behavioral responses that affect biological processes in response to 
traumatic stress, depression, physical symptoms and ultimately health behavior outcomes 
(Andersen et al., 1994; Golden-Kreutz et al., 2005).  
Sample Characteristics 
The BCS collected demographic variables that included Age, Ethnic Identity, 
Education, Menopausal status and Stage of Breast Cancer at diagnosis. Demographic data 
with background sample characteristics is summarized in Table 1. The age of participants 
was (M = 59.3); (S.D. 6.67). Education levels included (27.5%) Masters or above, (30%) 
Bachelors, (10%) Associates and (13%) with some college. The most frequently reported 
stage of cancer in this sample was Stage 1 at (69.2%). The remaining sample was (Stage 
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2- 7.7 %); (Stage 2- 18%;) and (Stage 3–5%). Within this sample (79.4%) were 
postmenopausal and (20.6%) were premenopausal. The sample (N= 40), revealed that 
participants were prescribed (85%), Aromatase Inhibitors (AIs) and the other (15%) 
participants were prescribed Tamoxifen. The comparison of background characteristics 
can be viewed in Table 1.  
Table 1 
Demographic/Descriptive Frequencies 
Characteristic Frequency (%) 
Ethnicity  
Caucasian 37 (92.5%) 
African American 0 (0.0%) 
Hispanic 0 (0.0%) 
Asian/Pacific Islander 1 (2.5%) 
American Indian 1 (2.5%) 
Mixed 1 (2.5%) 
Education  
Less than high school 1 (2.6%) 
High school/GED 3 (7.7%) 
Some College 5 (12.8%) 
Associates/2 yr degree 4 (10.3%) 
Bachelor/4 yr degree 12 (30.8%) 
Masters degree 11 (28.2%) 
Doctorate/Professional degree 3 (7.7%) 
Menopause Status  
Premenopausal 7 (20.6%) 
Postmenopausal 27 (79.4%) 
Breast Cancer Stage  
Stage 0 3 (7.7%) 
Stage 1 27 (69.2%) 
Stage 2 7 (17.9%) 
Stage 3 2 (5.1%) 
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Data Collection and Response Rate 
The collection of data was performed in person, telephone and with the 
medication event monitoring system (MEMS). The data collection occurred in a series of 
steps. (1) Participants filled out the Breast Cancer Survey (BCS) during the initial 
meeting with the researcher (2) The MEMs caps were provided for each participant with 
instructions during the initial meeting (3) Participants received two unannounced phone 
calls to obtain a pill count. During these calls two items on the Pill Count Form were used 
to determine if participants missed any doses of medication. These two items were 
divided into intentional and unintentional non- adherence. Medication Possession Ratio 
(MPR) for a pill count was not used due to the inaccuracy of this self- report measure. 
Patients were unable to remember the dates the medication was filled and prescriptions 
were changed from a 30 day to 90 day supply in the middle of the study period. Due to 
these issues the pill count was consistently inaccurate over the study period. 
The BCS contains the instruments measuring depression, traumatic stress and 
symptom distress. Adherence measurements were obtained over the course of the study. 
The response rate for BCS was (N = 40), indicating 100% response rate of the 
participants. The new adapted PDS scale was taken out of the data analysis due to high 
multicollinearity problems with the other instruments. This new scale was an investigator 
created measurement based on a review of numerous symptom distress scales.  
Missing Data 
All participants within the study completed the BCS measure. For any questions 
in the survey that were left unanswered, the typical answer from the participants’ total 
scale was used for this missing data. There were 2 cases out of the total of 40 participants 
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that had missing adherence data, These two participants both stopped medication due to 
side effects. One participant complained of severe memory loss. The other participant 
experienced severe anger and mood swings that she attributed to the medication. All 
missing data in the analysis of the MEMS data was treated as missing data and no effort 
was made to impute scores for this missing data.  
Descriptives 
All the participants filled out the BCS (N=40) measuring depression, traumatic 
stress and symptom distress. The BCS was adapted from the CES, IES, and the new 
adapted investigator created psychological symptom distress (PDS) scale. In this study 
the mean, standard deviation, skewness and kurtosis were evaluated for all these 
instruments. The CES-D is a 20 item scale and contains 4 constructs / subscales 
including: depressed affect, positive affect, somatic activity, and interpersonal. The CES-
D utilizes a four point Likert type response scale of Rarely (0) Some of the Time (1) 
Occasionally (2), and Most of the Time (3). Four of the items needed to be reverse scored 
in the CES-D. The IES is a 15-item scale that contains two subscales of intrusion and 
avoidance. The Intrusion subscale has 7 items rating intrusive thoughts, intrusive 
feelings, nightmares, and imagery associated with the traumatic event. The Avoidance 
subscale has 8 items rating avoidance of emotions, ideas, and situations. The scoring on 
this scale was a Likert type response scale, however responses are weighted Not at all (0) 
Rarely (1) Sometimes (3) Often (5). Due to an error there were 14 items used for this 
scale in this study, there was no effort made to impute scores for this missing item.  
  The MEMS data was converted from the MEMS data program to interval 
variables where it was recorded every 30 days to interval data. Unintentional data was 
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scored on a Likert type scale of Never (0) Occasionally (1) Sometimes (2) Quite often (3) 
Very often (4). Intentional was scored on the same Likert type scale of Never (0) 
Occasionally (1) Sometimes (2) Quite often (3) Very often (4). Intentional / Unintentional 
Non Adherence (NA) scores are the average number of the two phone call interviews 
with participants. The Total Non Adherence score is the sum of the Intentional / 
Unintentional scores. Table 2 displays the descriptive statistics for the study variables. 
Table 2  
Descriptive Statistics for Study Variables 
     Non-Adherence Ratio 
  Age CES IES MEMS Unintentional Intentional Total 
N Valid 
(Missing) 40 (0) 40 (0) 40 (0) 39 (1) 38 (2) 38 (2) 38 (2) 
Mean 59.330 10.421 15.840 0.150 0.618 0.211 0.829 
Median 59.500 10.000 14.000 0.052 0.500 0.000 1.000 
Std. 
Deviation 6.677 7.344 10.153 0.258 0.586 0.694 0.872 
Skewness -0.500 0.483 0.639 2.537 0.360 4.751 1.624 
Kurtosis -0.021 -0.410 0.135 5.884 -0.964 25.185 4.109 
 
PDS 
N Valid (Missing) 40 




Kurtosis 1.39  
 
Typically the normal value of skewness and kurtosis is -1 to +1. Review of Table 
2 indicates the instruments CES and IES were within acceptable limits. The MEMS data 
was not within acceptable limits of normality. Unintentional data was within normal 
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limits. Intentional data was not within normal limits. The total score was not within 
normal limits. The PDS is not within normal limits of +1 to -1.  
Figures 3 through 6 provide descriptive characteristics for the distribution of Age, 
CES-D, IES, and MEMS. In Figure 3., the descriptive statistics for the age of breast 
cancer survivors in this sample are displayed. For study participants (N=40) the average 
age was (59.3) years old. Overall, breast cancer is more common in Caucasian women, 
however less common under the age of 45 years old. The majority of this sample (92%) 
was Caucasian and this should be considered in these results. The chance of developing 
breast cancer increases with age in all populations. Although, under the age of 45 years 
there is a higher incidence in African-American women and the mortality rate is higher. 
Over the next 10 years, at the following ages the risk to develop breast cancer is as 
follows; 1.47% (or 1 in 68) at 40 years old, 2.38% (or 1 in 42) at 50 years old, 3.56% (or 
1 in 28) at 60 years old and 3.82% (1 in 26) at 70 years old. As shown by these recent 
statistics age is a risk factor for developing breast cancer with 85% diagnosis over 45 
years of age. Figure 3 displays the descriptive characteristics for the age distribution for 
the sample of (N=40) in this study.  
The possible range of scores on Figure 4 is between 0-60, and a score of 16 or 
higher is considered depressed. In studies using the CES-D to screen for depression in 
Hepatitus C, Spinal Cord Injury and Chronic Stroke, the average mean score was (17.74). 
(Miller, Anton, & Townson, 2007; Clark, Mahoney, Clark, & Eriksen, 2002; Shinar et al., 
1986). In comparison this sample of breast cancer survivors (N=40) with a mean score of 




Figure 3. This figure displays the age distribution of participants. This histogram 





Figure 4 displays the distribution for CES-D scores.  
 
Figure 4: The CES–D distribution is skewed to the left and is positive. The mean 
is (10.42) and the standard deviation is (7.34).  
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Figure 5 displays the Impact of Event (IES) distribution for the participants in  
this study.  
 
Figure 5. IES is skewed to the left and is positive. The (mean = 15.84) and the 
(standard deviation = 10.15). 
The range of scores on this scale are 0-44, with a cutoff of 25 indicating high 
levels of traumatic stress. Comparison of normative data for the IES was performed by 
Corcoran and Fischer (1994), within samples of individuals that were experiencing 
grieving related to the loss of a parent. The comparison of these studies with the current 
study of breast cancer survivors indicate the current results are within the same range of 
response scores. The grieving subjects average score of (mean= 16.23) with an average 
(standard deviation = 9.2) was similar to the results obtained in this study.  
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Figure 6 displays the (MEMS) distribution.  
 
Figure 6. MEMS non-adherence ratio. The MEMS non-adherence ratio is the 
average number of days a participant did not open the MEMS bottle, divided by 
the average number of days a participant had the bottle. The (mean = 15.04) and 
the (standard deviation is 25.79). The majority of these participants had a 
moderate to high adherence rate of 85%.  
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Figure 7 displays the Unintentional Non Adherence distribution.  
 
 
Figure 7. Unintentional Non Adherence. The Unintentional Non Adherence is 
calculated by the average of the scores for the two phone call interviews. 
Unintentional data was scored on a Likert type scale of Never (0) Occasionally 
(1) Sometimes (2) Quite often (3) Very often (4). The values (N = 38)  
(mean= .6184) and the (standard deviation = .5863). The Unintentional Non-






 Figure 8 displays the Intentional Non-Adherence distribution.  
 
Figure 8. Intentional Non Adherence. The Intentional Non Adherence is 
calculated by the average of the scores for the two phone call interviews. 
Intentional data was scored on a Likert type scale of Never (0) Occasionally (1) 
Sometimes (2) Quite often (3) Very often (4). The Intentional Non-Adherence is 
calculated (N= 38); (mean = .2105); (standard deviation = .6939). The Intentional 
Non-Adherence data was obtained with the question: How often do you choose 
not to take your medication? 
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Figure 9 displays the Total Non Adherence distribution.  
 
Figure 9. Total Non Adherence. The total non-adherence ratio is calculated by 
adding the average number of days a participant forgot to take their medication 
(Unintentional) and the average number of days they chose not to take their 
medication (Intentional). The Total Non Adherence is calculated (N=38); (mean = 




Internal consistency of the BCS was analyzed to determine reliability in the study 
sample (n = 40). The CES and IES constructs consist of traditional, multi-item scales. 
Cronbach’s alpha was computed for each of these scales and was found to indicate 
acceptable reliability in each case. Reliability measures for the CES, IES and SDS can be 
viewed in Table 3. 
Table 3 
Reliability Measures  
Scale n (items) 
Cronbach's 
Alpha 
CES 19 0.821 
IES 14 0.836 
PDS 14 0.833 
 
 
The CES-D and IES are scales that have been used consistently for many years in 
many different studies including breast cancer. They are both scales that are considered 
reliable and valid instruments. The PDS scale was an investigator created scale, although 
the Cronbach alpha score is high, there is a validity problem with the PDS due to high 
multicollinearity with the depression measure, the CES-D. 
Hypothesis Testing 
The hypothesis testing was carried out using multiple regression stepwise method 
to determine if a relationship exists between the dependent variable of adherence and the 
predictors of depression, traumatic stress, intentional non adherence and unintentional 
non adherence. Multiple regression is an appropriate choice for developing a model to 
predict whether or not an individual adheres or does not adhere to a drug regimen. 
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Sequential or hierarchical regression was used to assess the contribution of descriptive 
variables to the model. A stepwise multiple regression was also used to assess the 
contribution or variance accounted for by each of the predictor variables, the subscales 
and unidimensional scale scores. Stepwise multiple regression is often referred to as a 
statistical multiple regression. 
Hypothesis Tests 
The correlation matrix in Table 4 reveals there is no correlation between CES and 
IES (p= 0.072); (r= .29). CES and Intentional NA (p = 0.083); (r=.29) are not significant. 
IES and Intentional NA (0.014); (r=.40) indicates significance with a moderate to strong 
relationship. MEMS NAR and Intentional NA (p = 0.002); (r=.481) indicates significance 
with a moderate to strong relationship. MEMS NAR and Total NAR (.013); (r=.40) 
indicates a moderate relationship. Unintentional and Total NA (p = 0.001); (r= .88) 
indicates a strong relationship. Intentional NA and Total Non Adherence (.001); (r=.74) 
indicates a strong relationship. The Total Non-Adherence (NA) is the sum of intentional 
non adherence and unintentional non adherence. PDS and Intentional NA (.001); (r=.54) 
indicates a strong relationship. PDS and MEMS NAR (.015); (r=.39) indicate a moderate 
relationship. PDS and Total NA (.008); (r=.43) indicate a moderate relationship. Further 
analysis was performed with stepwise multiple regression, testing the two hypothesis.  
Table 5 displays the bivariate correlations between the psychological symptom 
distress scale (PDS) and the measures of MEMS Non Adherence Ratio (NAR), 





Correlation Matrix: CES, IES, and NAR 
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Table 5 
Correlations: PDS and NAR 
 PDS 
MEMS NAR 0.387 (0.015) 
Unintentional NA -0.005 (0.974) 
Intentional NA 0.539 (<0.001) 





What is the impact on adherence of traumatic stress, depression, and symptom 
distress?  Model 1 does not create significant additional predictive value over the null 
model (Table 6). The total predictive capacity of the model is extremely weak 
(R2=0.039).  
Table 6 
Multiple Regression Model: CES and IES as Predictors of MEMS Non-adherence Ratio 
     Coefficients 
Model Independent Variable R R
2 p (Change) Beta T p 
1 CES 0.198 0.039 0.488 0.184 1.079 0.288 
  IES       0.035 0.206 0.838 
 
Model 1 does not create significant additional predictive value over the null 
model. The total predictive capacity of the model is extremely weak (R2=0.039). 
 
Table 7 
Multiple Regression Model: CES, Avoidance, and Intrusive as Predictors of MEMS 
Non-Adherence Ratio 
     Coefficients 
Model Independent Variable R R
2 p (Change) Beta t p 
1 CES 0.198 0.039 0.701 0.180 0.972 0.338 
 Avoidance    0.014 0.075 0.940 





What is the impact on intentional/unintentional adherence of traumatic stress, 
depression, and symptom distress? 
 
Table 8 
Multiple Regression Model: CES and IES as Predictors of Intentional, Unintentional, 
and Total Non-Adherence Ratios 
	  





2 p (Change) Beta t p 
Intentional 1 IES 0.396 0.157 0.014 0.396 2.591 0.014 
 2 IES 0.435 0.189 0.247 0.343 2.161 0.038 
   CES       0.187 1.177 0.247 
Unintentional 1 CES 0.096 0.009 0.851 -0.081 -0.460 0.648 
  IES    -0.033 -0.191 0.850 
Total 1 CES 0.292 0.085 0.211 0.094 0.560 0.579 
   IES       0.251 1.486 0.146 
	  
For Intentional Non-Adherence Ratio, Model 1 creates a significant additional 
predictive value over the null model. However, Model 2 fails to create significant 
additional predictive value over Model 1. Therefore, Model 1 is the most parsimonious, 
and IES is the only significant predictor of Intentional Non-Adherence Ratio (R2=0.157). 
For Unintentional and Total Non-Adherence Ratio, each respective Model 1 fails to 
create additional predictive capacity over the null model. Thus, neither CES nor IES is a 







Multiple Regression Model: CES, Avoidance, and Intrusive as Predictors of Intentional, 
Unintentional, and Total Non-Adherence Ratios 
	  
      Coefficients 
Non-Adherence 





Beta t p 
Intentional 1 CES 0.438 0.192 0.062 0.166 0.958 0.345 
  Avoidance    0.184 1.062 0.296 
   Intrusive       0.232 1.207 0.236 
Unintentional 1 CES 0.159 0.025 0.830 -0.028 -0.146 0.885 
  Avoidance    0.089 0.471 0.641 
  Intrusive    -0.159 -0.756 0.455 
Total 1 CES 0.295 0.087 0.369 0.114 0.617 0.542 
  Avoidance    0.206 1.122 0.270 
   Intrusive       0.077 0.379 0.707 
	  
The IES subscales of Avoidance and Intrusive failed to create a better model 
separately, as opposed to the combined IES.  
Summary 
The predictor variables, traumatic stress, depression, and symptom distress, were 
used to determine their contribution to the dependent variable of adherence to adjuvant 
hormonal therapy and intentionality. A correlational regression prediction design was 
used to develop a model for predicting adherence or intentionality with traumatic stress, 
depression, and symptom distress as the predictor or independent variables. Prior 
research has documented the connection between depression, traumatic stress and 
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symptom distress with a lack of adherence. The results of this analysis will be discussed 





The purpose of this study was to examine the relationship between adherence and 
traumatic stress, depression, and symptom distress. The study also sought to determine 
whether or not non adherence is intentional or unintentional. This study explored the 
reasons breast cancer survivors are non- adherent to adjuvant hormonal therapy. Different 
types of adherence were examined in this research to provide a greater understanding of 
the problem. The following research questions were used to guide the design and analysis 
for this study: RQ1: What is the impact on adherence of traumatic stress, depression, and 
symptom distress? RQ2: What is the impact on intentional/unintentional adherence of 
traumatic stress, depression, and symptom distress? 
Major Findings 
The most significant finding in this study was that trauma measured by the IES 
predicted Intentional non adherence, this is an important finding that has not been shown 
before in the literature. This result supports the hypothesis that trauma is a predictor of 
non adherence. The experience of being diagnosed and treated for breast cancer can elicit 
a traumatic stress reaction similar to post traumatic stress disorder (PTSD). These 
symptoms can manifest as fear, hopelessness, helplessness, depression, anxiety, 
insomnia, nightmares, fears of reoccurrence, irritability, avoidance, intrusive thoughts, 
anger, hyperarousal, dissociation and intermittent memory loss (APA, 2013; NCI, 2009; 
Kwekkeboom & Seng, 2002). 
The IES measure was the only highly significant predictor of Intentional non 
adherence. This indicates the participants that Intentionally chose not take their 
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medication are possibly experiencing traumatic stress. The impact of event scale (IES) 
has been used for over three decades to assess psychological stress following any major 
life event and has been validated in cancer studies (Horowitz et al., 1979; Mennert & 
Koch, 2007). 
The IES is a widely applicable self-report measure designed to assess current 
subjective distress for any specific life event (Corcoran & Fischer, 1994; Horowitz et al., 
1979). The IES consists of 15 items and is a standardized self-report examining 
cognition involving re-experiencing. The IES has two main subscales that include 
Intrusion (7 items) and Avoidance (8 items). These items are highly correlated with the 
DSM-V listed symptoms for the diagnosis of PTSD. The Intrusion subscale has 7 items 
rating intrusive thoughts, intrusive feelings, nightmares, and imagery associated with the 
traumatic event. The Avoidance subscale has 8 items rating avoidance of emotions, ideas, 
and situations. The IES was adapted for cancer patients by slight rewording of the items 
by replacing the word ‘it’ with cancer. 
Research has shown that individuals experiencing a cancer diagnosis experience 
traumatic stress (Mennert & Koch, 2007; Pujol et al., 2013). The two most common 
symptoms of traumatic stress can be avoidance and intrusion. Both of these items are 
measured with the subscales of the IES. These findings may indicate that participants 
were unconsciously avoiding their medication because it was a reminder of their breast 
cancer. Norton et al. (2010) suggests that intentional non- adherence may be associated 
with avoidant behaviors. The diagnosis and treatment of breast cancer is considered a life 
threatening event (APA, 2013). The experience of traumatic stress occurs in response to 
the perception of a serious threat that occurs suddenly and is perceived as uncontrollable. 
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Traumatic stress may predispose an individual to PTSD symptoms that include 
nightmares, intrusive thoughts, avoidance, detachment, hyper arousal, decreased 
concentration, irritability and insomnia (NCI, 2009; Guervich et al., 2002). 
There may be many reasons an individual chooses not take their medication. This 
particular sample did not reveal why they chose not to take their medication. When asked 
if there was a reason they chose not to take their medication subjects said they did not 
know or could not remember. Overall, adherence to most medication is suboptimal, with 
an estimated average of 50% (Haynes et al., 2002). Although studies have identified 
many predictors of non adherence, the majority of these studies have mixed and 
inconclusive results.  
What is Known About Adherence 
Despite many studies being performed on adherence the overall knowledge of this 
concept is limited, particularly the psychological aspect of this problem. The lack of 
conformity in adherence terminology and lack of a gold standard in measurement 
contributes to the difficulty in the comparison of studies and inability to consistently 
identify predictors of decreased adherence (Hadji, 2010;Volovat et al, 2010). Although, 
over 50 years of research on adherence to treatment recommendations has provided 
a vast amount of literature, there are major gaps in understanding the fundamentals of 
adherence, particularly in breast cancer survivors.  
Most research has emphasized the behavioral aspect of adherence while the 
biological response, spiritual dimension and emotional influence on behavior outcome 
has been overlooked (Andersen et al., 1994; DiMatteo, 2004; Glaser & Keicolt-Glaser, 
2005; Moreno-Smith et al., 2010). This unidimensional focus has minimized the ability to 
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adequately research adherence in serious illnesses such as breast cancer. This is important 
because research indicates there is a bi-directional flow of response between 
psychological factors and biological changes that are shown to affect behavior outcomes 
such as adherence (Andersen et al., 1994; Miller & Raison, 2008; Starkweather et al., 
2011). 
Biobehavioral Mechanisms of Adherence 
Current and past research indicates there is a bi-directional flow of interaction 
between psychological factors, neuroendocrine, and immunological responses at the 
biologic cellular, and molecular level and each has an affect on behavioral change, 
(Andersen et al., 1994; Miller & Raison, 2008; Starkweather et al., 2011), modulate 
neurocognitive change, and psychological responses (Dantzer & Kelley, 2007; 
Raghavendra et al., 2004). Trauma is a psychological response that can cause biological 
changes that may affect behavior outcomes such as adherence. The results of this study 
indicate there was a connection between trauma and Intentional non adherence. The 
diagnosis of cancer has been considered one of the most stressful events that can occur in 
a person’s life. The American Psychiatric Association (APA) has determined that being 
diagnosed with cancer or any life threatening illness meets criteria for a traumatic event 
(APA, 2013). 
The link between the behavioral response to perceived stress and biology is 
referred to as biobehavioral. This study used a biobehavioral framework to examine the 
problem of adherence to adjuvant hormonal therapy in breast cancer survivors.  
The specific focus of the model includes the Biobehavioral Model of Cancer 
Stress. The Biobehavioral Model of Cancer Stress (Andersen et al., 1994) framework for 
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research refers to a focus on the interrelationships of psychological stress, behavioral and 
the biological processes in disease and the treatment of disease. This theoretical 
framework was selected because previous research has emphasized the behavioral aspect 
of adherence, while the psychological, spiritual, environmental and biological influences 
on health behavior outcomes, within a biobehavioral framework has been unknown or 
overlooked (Bultz &, Carlson, 2006; DiMatteo et al., 2000; Kirton & Morris, 2013; 
Moreno-Smith et al., 2010; Shemish et al., 2004). Although this study did not directly 
measure the biological markers associated with traumatic stress, symptom distress, and 
depression the study did examine the relationship between adherence and intentionality 
within a biobehavioral framework. 
Methods of Measurement 
This study used indirect measurements of medication adherence including MEMS 
bottles and self- report measures. The literature on adherence research recommends using 
several different methods to measure this variable. Currently, there is no gold standard 
for measuring indirect or direct medication adherence. Indirect measures include 
counting pills, electronic monitoring techniques, self-report questionnaires, medication 
diaries and chart reviews. Direct measures of adherence include drug metabolite 
measurements of the urine or blood and observation of patients taking medication. 
Self-report with a phone interview was used to obtain the Intentional / 
Unintentional non adherence data for this study. This data was collected using the 
following questions, 1) Intentional non adherence: how often do you choose not to take 
your medication? and 2) Unintentional non adherence: how often do you forget your 
medication? Self-report method with a phone interview or e-mail has been validated with 
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other measures in numerous studies including cancer, using a multimethod approach 
(Baker & Brandon, 1990; Steele et al., 2007). Direct questioning of patients to evaluate 
adherence may improve the reliability of self-report. Adherence measurements in cancer 
therapy have been based primarily on self-report measures (Partridge et al., 2002).  
There are mixed results regarding the accuracy of self-report measures. Several 
studies indicate self-reported adherence rates may be higher if patients know they are 
being monitored (DiMatteo & Haskard, 2006; Partridge et al., 2008; Ziller et al., 2009). 
The current study used several different methods of measurement for adherence to 
improve reliability. At this time there is minimal empirical research using a standardized 
definition for adherence validating the reliability of self-report measures in cancer 
populations (Escalada & Griffiths, 2006; NCI, 2009).  
The primary adherence measure for this study was the Medication Event 
Monitoring System (MEMS) caps. MEMS are medication bottles that contain a 
microchip in the lid. The microchip electronically records the date and time the pill bottle 
is opened (Cook, et al., 2011; Diaz et al., 2001). Adherence using this method was 
calculated as the percentage of doses taken over the study period, with 85% of the total 
doses taken considered adherent. The MEMS data in this study was measured at multiple 
time points, these measurements occurred every time the bottle was opened. Although 
MEMS are an indirect measurement, many researchers consider MEMS to be a more 
objective method of measurement. Despite this belief there are still some concerns and 
questions about this measure. The concerns about MEMS include the possibility of a 
Hawthorne effect, or if opening the MEMS bottle actually reflects real pill taking 
behavior, and whether this method is consistent with other adherence measurements 
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(Cook et al., 2011). To address these concerns multiple methods of measurement were 
used in this study. Self-report measurements have a moderate to high correlation of 
adherence with Medication Electronic Measurement Systems (MEMS) (Haynes, Taylor, 
Sackett, Gibson, Bernholz, & Mukherjee, 1980). The use of self-report and MEMS 
measures proved to be effective methods for this research. 
Findings 
Impact of Traumatic Stress, Depression and Symptom Distress on Adherence  
The primary variable in this study was non adherence. The predictor variables 
include depression and traumatic stress. The variables of depression and traumatic stress 
did not show a correlation with the MEMS non adherence (NA) in this sample. The small 
sample may be a contributing factor in this result, with a larger sample there is potential 
that a greater significance level could exist. The IES, CES and the MEMS non adherence 
did not show a correlation.  
The MEMS NA and Intentional NA (self-report) were highly correlated and 
significant (r= 0.481); (p= .002). This finding is supported by the literature in that MEMS 
has been shown to correspond with drug level testing, interviews conducted by clinicians 
and self- report measures (Cook et al., 2011; Hugen et al., 2002). The high correlation 
between the MEMS NA and Intentional non adherence (NA) indicate the self-report 
measure and MEMS correspond. Despite this correlation the multiple regression analysis 
did not indicate that trauma predicted the MEMS non adherence, as shown with 
Intentional non adherence.  
An unexpected finding in this study was that subjects did not over estimate their 
self -report adherence levels. Many studies have reported that self-report measures of 
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adherence are higher than the actual adherence rate (DiMatteo & Haskard, 2006; 
Partridge et al., 2008; Ziller et al., 2009). In this study the MEMS non adherence and the 
self-report measure of Intentional non adherence were highly correlated. MEMS is not a 
self-report measure and is considered a more objective measure that can be used to 
validate self-report measures. 
The MEMS non adherence (NA) and Total non adherence (NA) had a moderate 
correlation (r=.40); (p=0.013). Intentional and Unintentional NA (self-report measures) 
were both highly correlated with the Total non adherence (NA). Intentional NA and Total 
NA ( r=0.74); (p=0.001) indicate a high correlation with significance. Unintentional NA 
and Total NA (r=0.61); (p=0.001) indicate a strong correlation with high significance. 
The Total NA is the sum of the number of days for Intentional NA and Unintentional NA 
both are self-report measures, therefore the sum of the self-report measures in the study.  
The Multiple Regression Model analyzing the CES and IES as predictors of 
MEMS Non-Adherence Model did not create significant additional predictive value over 
the null model. The total predictive capacity of the model is extremely weak (R2=0.039). 
The CES values (p = 0.288) and (t = 1.079). The IES values (p = 0.838 and (t = 0.206). 
These results indicate there is not a correlation between the MEMS NA and the predictor 
variables of depression and traumatic stress. This particular statistical analysis indicates 
these breast cancer survivors were not experiencing a significant amount of depression 
when filling out the Breast Cancer Survey. 
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Impact of Traumatic Stress, Depression and Symptom Distress on 
Intentional/Unintentional Adherence  
The second hypothesis asks if traumatic stress, depression, and symptom distress 
scales or subscales are predictors of intentionality to adhere or not adhere to a treatment 
regime. The CES-D did not predict Intentional non adherence (NA) or Unintentional NA 
Results for Intentional NA are the following: The IES and the Intentional NA (r=0.40);  
(p = 0.014) are very significant with a strong correlation. Intentional NA and MEMS NA 
(p=0.48); (p=0.002) indicates a strong correlation and high significance. The third 
variable in the analysis the Total NA is the sum of the Intentional and Unintentional NA 
self-reports. Intentional NA and the Total NA, (r=0.74); (p=0.001) indicates a strong 
correlation and high significance.  
Results for Unintentional NA are the following: Unintentional NA and Total NA 
(r=0.61); (p=0.001) indicates strong correlation and high significance. There is a very 
significant relationship between Unintentional Non Adherence and the Total NA.  
The Multiple Regression Model testing the CES and IES as Predictors of 
Intentional, Unintentional, and Total Non-Adherence Ratios created a significant 
additional predictive value over the null model. IES was the only highly significant 
predictor of the Intentional Non- Adherence Ratio (R2 = 0. 157). For the Unintentional 
and Total Non adherence, the respective models failed to create additional predictive 
capacity over the null model. Therefore, CES and IES are not significant predictors of 
Unintentional Non-adherence Ratio or Total Non-adherence Ratio.  
These results indicate there is a strong correlation between the Intentional NA and 
the IES. This suggests that participants choosing not to take their medication may be 
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experiencing a higher level of traumatic stress. There is also a strong relationship 
between the Intentional NA and the MEMS NA. This indicates the self- report measure 
and MEMS are both predicting non adherence.  
Sample Characteristics 
The mean age (M = 59.3) of participants and (92. 5%) of volunteers were 
Caucasian. Education in this sample was high with (71%) of subjects having an Associate 
degree or higher of education. A large percentage (79%) of participants were 
postmenopausal. There are two possible reasons for a larger percentage of 
postmenopausal women that include; Age (M= 59.3) and the fact that adjuvant hormonal 
therapy can potentiate early menopause. The vast majority (75.9%) of participants had 
breast cancer Stage 0 and Stage 1. This factor should be considered in the results of this 
research, since a lower Stage of breast cancer has a lot to do with survival statistics. 
Individuals with lower stage of breast cancer may also experience less depression.  
Limitations 
This study attempted to explore the multidimensional quality of non- adherence to 
adjuvant hormonal therapy in breast cancer survivors. The outcome of this study may 
have been influenced by many factors including education level, socioeconomics, stage 
of breast cancer, environment and other elements that were not considered.  
There was no threat from interaction between subjects and treatment; however, 
using volunteers does present a problem. These subjects may have characteristics atypical 
of the general population, this sample was (92.5%) Caucasian and (59%) of participants 
had a bachelor degree or higher level of education. These characteristics limit the ability 
to generalize this sample. 
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Education regarding the use MEMS caps may not have been clear to at least one 
participant in the study. MEMS data indicated one participant opened and closed the 
bottle every 7 days, most likely this subject was taking out the medication and putting it 
in another container. Monthly scores for the MEMS data appeared normal for other 
participants, however when the MEMS bottle is opened it does not mean a pill is taken. 
The self-report measures of intentional/ unintentional were investigator created tools, 
although these questions have been used in other studies they are not standardized. The 
use of different instruments may have improved the knowledge and results in this study.  
Ecological validity is concerned with generalizing of the study results to other 
situations. Individuals in the study were recruited from numerous different sites. Most of 
these volunteers came from facilities that accept insurance, very few Medicaid patients 
were in the study. Participants knowledge that they would be called to check on their 
adherence may have affected the volunteers desire to take their medication. These factors 
again limit the ability to generalize this sample. A larger sample would have possibly 
shown a greater level of significance with the results. Recruiting a more diverse 
population most likely would have increased the significance level of these findings.  
Implications of Results 
The implications of these findings support the view that adherence or non 
adherence should be measured with multiple instruments and in diverse ways. This can 
be done by acknowledging that there are many different types of adherence or non 
adherence. This construct may have a different meaning to various individuals and this 
should be considered in the research.  
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Intervention strategies for traumatic stress include cognitive behavioral therapy 
(CBT) within group or private settings. Individual existential psychotherapy or groups, 
and solution focused therapy. Exercise groups and yoga specifically designed for cancer 
patients. Hypnosis has been shown to be effective for improving anxiety. Learned 
meditative practices for relieving anxiety associated with traumatic stress has been shown 
to improve anxiety symptoms (Holland & Allici, 2010; Holland & Bultz, 2010). 
Psychopharmacology is also an option based on American Psychiatric Association 
guidelines for the treatment of depression, anxiety and traumatic stress (APA, 2015). 
The implications for healthcare professionals include; the knowledge that many 
factors are involved with following a medication regimen that is prescribed. Regular 
screening for traumatic stress in cancer patients is essential (Holland & Bultz, 2010). 
Clinical practitioners should remember that what we see with our eyes is not always what 
is actually occurring. Adherence or non adherence is not necessarily a representation of 
an individuals’ desire to maintain health and wellbeing.  
For nursing in particular, the knowledge that we can be an integral part of the 
healing process is essential. Through education, example and observation, patients learn 
how to care for themselves. Understanding theoretical guidelines that promote a healing 
structure is necessary in nursing to navigate effective patient care. The promotion of 
health requires expertise and knowledge beyond academic learning, it is based on 
principles that promote healing from an ethical and authentic platform.  
According to Martha Rogers (1990), the human environmental field interaction is 
dynamic and infinite. Considering this perspective healing is contained within the greater 
field between patient, environment and nurse. The energy field holds the potential of 
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healing according to the level of awareness and intention from the nurse, environment 
and patient. Within the Science of Unitary Human Beings (SUHB) paradigm health is 
referred to as a higher frequency of functioning. Activities that promote this change in 
pattern include; performing healthful behaviors in relation to the environment such as 
increasing lighting, the use of harmonious sound, maintaining and improving creativity, 
and patterning related to balance in the energy exchange with the environment. This can 
include very basic activities such as active listening, referrals, compassionate caring 
exchange, and exercise.  
Summary 
There were several important findings in this research. First, that trauma predicted 
Intentional non adherence (NA). This indicates that adherence to treatment is affected by 
the traumatic nature of the cancer experience. Trauma is an issue that affects many 
individuals that experience a serious illness and clinicians should assess for this problem, 
and provide referrals and interventions. Second, that self-report measures of adherence 
are not necessarily reported inaccurately. Self-report measures with different populations 
may vary and are not always reported higher than the actual adherence levels. The use of 
multiple methods is absolutely essential in adherence research to determine the reliability 
of adherence reports. Third, that there are different types of adherence to treatment and 
there may not always be a clear reason for non- adherence. Healthcare professionals and 
researchers should maintain a neutral view of the problem to be effective. The primary 
focus of biomedical care is the treatment of physical health problems associated with 
cancer, while emotional, environmental, spiritual or psychological issues are frequently 
unrecognized (Lutofsky et al., 2004). Treatment adherence in breast cancer survivors is 
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an extremely complex phenomenon and requires a multifaceted, unifying 
theoretical perspective to capture the evidence. Finally, that adherence researchers should 
study trauma and become more aware of the psychological biological and behavioral 
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BREAST CANCER SURVEY (MS WORD VERSION FOR CLARITY) 
 
What is your age ___________________ 
Please circle one: Premenopausal Postmenopausal 
What is your ethnic identification  
! Caucasian    ! American Indian 
! African American   ! Mixed 
! Hispanic    ! Other 
! Asian/Pacific Islander 
 
Your completed educational level 
! Less than high school  ! Bachelor/4 year degree 
! High school/GED   ! Masters degree 
! Some college   ! Doctorate/Professional degree (Law, M.D.)  
! Associates/2 year degree 
 
The current state of your breast cancer 
Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 
Precancerous ! !  !   !  ! 







1 I am bothered by things that usually don’t 
bother me 
! ! ! ! 
2 I did not feel like eating; my appetite was 
poor 
! ! ! ! 
3 I feel I can not shake off the blues even with 
help from my family or friends 
! ! ! ! 
4 I feel I was just as good as other people ! ! ! ! 
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5 I have trouble keeping my mind on what I 
was doing 
! ! ! ! 
6 I feel depressed ! ! ! ! 
7 I feel that everything I do is an effort ! ! ! ! 
8 I feel hopeful about the future  ! ! ! ! 
9 I think my life has been a failure ! ! ! ! 
10 I feel fearful ! ! ! ! 
11 My sleep has been restless ! ! ! ! 
12 I am happy ! ! ! ! 
13 I talk less than usual ! ! ! ! 
14 I feel lonely ! ! ! ! 
15 People are unfriendly ! ! ! ! 
16 I enjoy life ! ! ! ! 
17 I have crying spells ! ! ! ! 
18 I feel sad ! ! ! ! 
19 I feel that people dislike me ! ! ! ! 
20 I can not get ‘going’ ! ! ! ! 
*Adapted from Center for Epidemiologic Studies Depression Scale (CES-D 
 
  Not at all Rarely Sometimes Often 
1 I think about cancer when I didn't mean to ! ! ! ! 
2 I avoided letting myself get upset when I 
think about cancer or was reminded of 
cancer  
! ! ! ! 
3 I try to remove cancer from memory ! ! ! ! 
4 I have trouble falling asleep or staying 
asleep, because of pictures or thoughts 
about cancer that come into my mind 
! ! ! ! 
5 I have waves of strong feelings about cancer ! ! ! ! 
6 I have dreams about cancer  ! ! ! ! 
7 I stay away from reminders of cancer  ! ! ! ! 
8 I feel as if cancer did not happened or the 
cancer was not real 
! ! ! ! 
9 I try not to talk about cancer  ! ! ! ! 
11 Pictures about cancer pop into my mind ! ! ! ! 




13 I am aware that I still have a lot of feelings 
about cancer, but I did not deal with them 
! ! ! ! 
14 I try not to think about cancer  ! ! ! ! 
15 Any reminder brings back feelings about 
cancer  
! ! ! ! 
* Adapted from the Impact of Event Scale (Horowitc, Wilner, & Alvarez, 1979) 
 During the past 7 days how 












1 Nervousness or shakiness inside ! ! ! ! ! 
2 Being suddenly scared for no reason  ! ! ! ! ! 
3 Feeling fearful ! ! ! ! ! 
4 Feeling tense or keyed up  ! ! ! ! ! 
5 Spells of terror or panic ! ! ! ! ! 
6 Feeling so restless you could not sit still ! ! ! ! ! 
7 Heavy feelings in arms or legs ! ! ! ! ! 
8 Feeling afraid to go out of your home 
alone 
! ! ! ! ! 
9 Feelings of worthlessness ! ! ! ! ! 
10 Feeling lonely even when you are with 
people 
! ! ! ! ! 
11 Feeling weak in parts of your body ! ! ! ! ! 
12 Feeling blue ! ! ! ! ! 
13 Feeling lonely ! ! ! ! ! 
14 Feeling no interest in things ! ! ! ! ! 
15 Feeling afraid in open spaces or on streets ! ! ! ! ! 



























PILL COUNT FORM 
 
